WO2019145386A1 - Oligonucléotides pour la modulation de l'expression de csnk1d - Google Patents

Oligonucléotides pour la modulation de l'expression de csnk1d Download PDF

Info

Publication number
WO2019145386A1
WO2019145386A1 PCT/EP2019/051684 EP2019051684W WO2019145386A1 WO 2019145386 A1 WO2019145386 A1 WO 2019145386A1 EP 2019051684 W EP2019051684 W EP 2019051684W WO 2019145386 A1 WO2019145386 A1 WO 2019145386A1
Authority
WO
WIPO (PCT)
Prior art keywords
antisense oligonucleotide
nucleosides
oligonucleotide
cancer
seq
Prior art date
Application number
PCT/EP2019/051684
Other languages
English (en)
Inventor
Peter Hagedorn
Lykke PEDERSEN
Original Assignee
Roche Innovation Center Copenhagen A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Center Copenhagen A/S filed Critical Roche Innovation Center Copenhagen A/S
Publication of WO2019145386A1 publication Critical patent/WO2019145386A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Definitions

  • the present invention relates to oligonucleotides (oligomers) that are complementary to casein kinase 1 delta (CSNK1 D) transcript.
  • oligonucleotides may be used for reducing CSNK1 D transcript in a cell, leading to modulation of the expression of CSNK1 D.
  • Modulation of CSNK1 D expression is beneficial for a range of medical disorders, such as cancers and, in particular breast cancer, liver cancer, lung cancer, cervical cancer, melanoma, glioblastoma,
  • pancreatic cancer pancreatic cancer
  • prostate cancer renal cancer, bladder cancer
  • endometrial cancer stomach cancer
  • a cancer that metastasizes to the brain, lymph nodes, lung, or bone metastasizes to the brain, lymph nodes, lung, or bone.
  • the casein kinase 1 delta (CSNK1 D) is a member of the casein kinase I (OKI) gene family of serine/threonine kinases whose members have been implicated in the control of cytoplasmic and nuclear processes, including DNA replication and repair.
  • the encoded protein may also be involved in the regulation of apoptosis, circadian rhythm, microtubule dynamics, chromosome segregation, and p53-mediated effects on growth.
  • the encoded protein is highly similar to the mouse and rat CK1 delta homologs.
  • WO/2017/066055 and Rosenberg et al., Sci Tranls Med., 2015, December 16; 7(318) relates to inhibition of CSNK1 D with a small molecule (SR-3029), and its use in the treatment of breast cancer, in particular of the triple negative subclass of breast cancers (TNBC) or HER+ breast cancer.
  • TNBC triple negative subclass of breast cancers
  • HER+ breast cancer a small molecule
  • WO2015/058056 also discloses inhibition of CSNK1 D and other CK1 family members using chemical compounds relating to N1 -methyl-pyrazoloanthrone.
  • CSNK1 D inhibition in liver cancer cell lines Huh7 and HepG2 indirectly reduces the expression of erythropoietin (EPO) gene expression due to reduction of Hif-2-phosphorylation. This is demonstrated using two siRNA’s. Reduction of EPO in hepatocelluar carcinoma may reduce vascularization and thereby reduce angiogenesis.
  • EPO erythropoietin
  • W02005/103240 and W02005/105987 relates to screening methods for identifying compounds that can regulate CSNK1 D isoform 1 or 2, respectively, and potentially be applied in a long list of diseases.
  • Antisense oligonucleotides are mentioned as one type of compound that can be screened, there are however no specific examples of any compounds that actually regulates CSNK1 D in the application.
  • Antisense oligonucleotides targeting repeated sites in the same RNA have been shown to have enhanced potency for downregulation of target mRNA in some cases of in vitro transfection experiments. This has been the case for GCGR, STST3, MAPT, OGFR, and BOK RNA (Vickers at al. PLOS one, October 2014, Volume 9, Issue 10).
  • WO 2013/120003 also refers to modulation of RNA by repeat targeting.
  • the present invention identifies novel oligonucleotides which down-regulate CSNK1 D expression and treat or prevent diseases related to the functioning of CSNK1 D.
  • the present invention provides antisense oligonucleotides capable of modulating CSNK1 D mRNA and protein expression, both in vivo and in vitro. Accordingly, the present invention can potentially be used in a combination therapy together with the known therapies for various types of cancer, such as breast cancer, liver cancer, melanoma, glioblastoma, medulloblastoma, renal, bladder or colon cancer, or a cancer that metastasizes to the brain, lymph nodes, lung, or bone.
  • the present invention provides antisense oligonucleotides, such as gapmer oligonucleotides, such as gapmer oligonucleotides, which are complementary to and target mammalian CSNK1 D nucleic acids, and uses thereof.
  • antisense oligonucleotides such as gapmer oligonucleotides, such as gapmer oligonucleotides, which are complementary to and target mammalian CSNK1 D nucleic acids, and uses thereof.
  • the present invention provides antisense oligonucleotides, which comprise contiguous nucleotide sequences, which are complementary to certain regions, or sequences present in target mammalian CSNK1 D nucleic acids.
  • the compounds of the invention are capable of inhibiting mammalian CSNK1 D nucleic acids in a cell, which is expressing the mammalian CSNK1 D nucleic acid.
  • the present invention provides for an antisense gapmer oligonucleotide compound targeting a mammalian CSNK1 D nucleic acid, and in vitro and in vivo uses thereof, and their use in medicine.
  • a first aspect the invention provides an antisense oligonucleotide of 10 to 50 nucleotides in length, which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity, such as fully complementary, to a mammalian CSNK1 D target nucleic acid, wherein the antisense oligonucleotide is capable of reducing the expression of the mammalian CSNK1 D target nucleic acid, in a cell.
  • the invention provides an antisense oligonucleotide wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 1 , 2, 3, 4, 5 and 6 or a naturally occurring variant thereof.
  • the invention provides an antisense oligonucleotide, wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to an intron region present in the pre-mRNA of mammalian CSNK1 D encoding target nucleic acid (e.g. SEQ ID NO 1 ).
  • the invention provides the antisense oligonucleotide, wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to a target region of SEQ ID NO 1 , selected from the group consisting of position 12898-12917, 12946- 12965, 13009-13028, 13033-13052, 13057-13076, 13168-13187, 13192-1321 1 , 13216-13235, 13240-13259, 13279-13298, 13303-13322, 13342-13361 , 13390-13409, 13453-13472, 13501 - 13520, 13547-13566, 13571 -13590, 13595-13614, 13651 -13670, 13675-13694, 13714-13733, 13738-13757, 13801 -13820; 12900-12917, 12948-12965, 1301 1 -13028, 13035-13052, 13059- 13076,
  • target region of 10-22 such as 14-20, nucleotides in length of the target nucleic acid of SEQ ID NO: 1 , wherein the target region is repeated at least 5 or more times across the target nucleic acid.
  • the invention provides the antisense oligonucleotide, wherein the antisense oligonucleotide, or contiguous nucleotide sequence thereof is selected from the group consisting of GAtgtgactgatggtgtaCT (Compound ID 17 1 ); GATgtgactgatggtGTA (Compound ID 18_1 ); ATGTgactgatggTGT (Compound ID 19 1 ) ; GTgactgatgGTGT (Compound ID 20_1 ); ACTgagtgatgtGACT (Compound ID 21 1 ); TGtactgagtgatgtgacTG (Compound ID 22 1 );
  • GTActgagtgatgtgaCT Compound ID 23_1
  • GTActgagtgATGT Compound ID 24 1
  • capital letters represent LNA nucleosides, such as beta-D-oxy LNA nucleosides
  • lower case letters represent DNA nucleosides
  • all LNA C are 5-methyl cytosine
  • at least one, preferably all internucleoside linkages are phosphorothioate internucleoside linkages.
  • the invention provides a conjugate comprising the antisense oligonucleotide according to the invention, and at least one conjugate moiety covalently attached to said oligonucleotide.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the oligonucleotide according to the invention or the conjugate according to some aspects of the invention, and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
  • the invention provides a pharmaceutically acceptable salt of the antisense oligonucleotide or conjugate according to the invention the invention.
  • the invention provides an in vivo or in vitro method for reducing mammalian CSNK1 D expression in a target cell which is expressing the mammalian CSNK1 D, said method comprising administering an oligonucleotide, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition according to the invention in an effective amount to said cell.
  • oligonucleotide the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition according to the invention to a subject suffering from or susceptible to the disease.
  • the invention provides a use of the oligonucleotide, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition for the preparation of a medicament for treatment, alleviation or prevention of cancers, such as breast cancer, liver cancer, lung cancer, cervical cancer, melanoma, glioblastoma, medulloblastoma, pancreatic cancer, prostate cancer, renal cancer, bladder cancer, endometrial cancer, stomach cancer, colon cancer, testis cancer, urothelial cancer, or a cancer that metastasizes to the brain, lymph nodes, lung, or bone.
  • cancers such as breast cancer, liver cancer, lung cancer, cervical cancer, melanoma, glioblastoma, medulloblastoma, pancreatic cancer, prostate cancer, renal cancer, bladder cancer, endometrial cancer, stomach cancer, colon cancer, testis cancer, urothelial cancer, or a cancer that metastasizes to the brain, lymph nodes, lung, or bone.
  • oligonucleotide as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides may also be referred to as nucleic acid molecules or oligomers.
  • Oligonucleotides are commonly made in the laboratory by solid-phase chemical synthesis followed by purification. When referring to a sequence of the oligonucleotide, reference is made to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides.
  • the oligonucleotide of the invention is man-made, and is chemically synthesized, and is typically purified or isolated.
  • the oligonucleotide of the invention may comprise one or more modified nucleosides or nucleotides.
  • Antisense oligonucleotide as used herein is defined as oligonucleotides capable of modulating expression of a target gene by hybridizing to a target nucleic acid, in particular to a contiguous sequence on a target nucleic acid.
  • the antisense oligonucleotides are not essentially double stranded and are therefore not siRNAs or shRNAs.
  • the antisense oligonucleotides of the present invention are single stranded.
  • single stranded oligonucleotides of the present invention can form hairpins or intermolecular duplex structures (duplex between two molecules of the same oligonucleotide), as long as the degree of intra or inter self-complementarity is less than 50% across of the full length of the
  • the antisense oligonucleotide of the invention comprises one or more modified nucleosides or nucleotides.
  • nucleotide sequence refers to the region of the oligonucleotide which is complementary to the target nucleic acid.
  • the term is used interchangeably herein with the term“contiguous nucleobase sequence” and the term“oligonucleotide motif sequence”. In some embodiments all the nucleotides of the oligonucleotide constitute the contiguous nucleotide sequence.
  • the oligonucleotide comprises the contiguous nucleotide sequence, such as a F-G-F’ gapmer region, and may optionally comprise further nucleotide(s), for example a nucleotide linker region which may be used to attach a functional group to the contiguous nucleotide sequence.
  • the nucleotide linker region may or may not be
  • Nucleotides are the building blocks of oligonucleotides and polynucleotides and for the purposes of the present invention include both naturally occurring and non-naturally occurring nucleotides.
  • nucleotides such as DNA and RNA nucleotides comprise a ribose sugar moiety, a nucleobase moiety and one or more phosphate groups (which is absent in
  • nucleosides may also interchangeably be referred to as“units” or “monomers”.
  • modified nucleoside or“nucleoside modification” as used herein refers to
  • nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the (nucleo)base moiety.
  • the modified nucleoside comprise a modified sugar moiety.
  • the term modified nucleoside may also be used herein interchangeably with the term“nucleoside analogue” or modified“units” or modified“monomers”.
  • Nucleosides with an unmodified DNA or RNA sugar moiety are termed DNA or RNA nucleosides herein. Nucleosides with modifications in the base region of the DNA or RNA nucleoside are still generally termed DNA or RNA if they allow Watson Crick base pairing.
  • modified internucleoside linkage is defined as generally understood by the skilled person as linkages other than phosphodiester (PO) linkages, that covalently couples two nucleosides together.
  • the oligonucleotides of the invention may therefore comprise modified internucleoside linkages.
  • the modified internucleoside linkage increases the nuclease resistance of the oligonucleotide compared to a phosphodiester linkage.
  • the internucleoside linkage includes phosphate groups creating a phosphodiester bond between adjacent nucleosides.
  • Modified internucleoside linkages are particularly useful in stabilizing oligonucleotides for in vivo use, and may serve to protect against nuclease cleavage at regions of DNA or RNA nucleosides in the oligonucleotide of the invention, for example within the gap region of a gapmer oligonucleotide, as well as in regions of modified nucleosides, such as region F and F’.
  • the oligonucleotide comprises one or more internucleoside linkages modified from the natural phosphodiester, such one or more modified internucleoside linkages that is for example more resistant to nuclease attack.
  • Nuclease resistance may be determined by incubating the oligonucleotide in blood serum or by using a nuclease resistance assay (e.g. snake venom phosphodiesterase (SVPD)), both are well known in the art.
  • SVPD snake venom phosphodiesterase
  • Internucleoside linkages which are capable of enhancing the nuclease resistance of an oligonucleotide are referred to as nuclease resistant internucleoside linkages.
  • At least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof are modified, such as at least 60%, such as at least 70%, such as at least 75% such as at least 80% or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are nuclease resistant internucleoside linkages.
  • all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof are nuclease resistant internucleoside linkages. It will be recognized that, in some embodiments the nucleosides which link the oligonucleotide of the invention to a non-nucleotide functional group, such as a conjugate, may be phosphodiester.
  • a preferred modified internucleoside linkage for use in the oligonucleotide of the invention is phosphorothioate.
  • Phosphorothioate internucleoside linkages are particularly useful due to nuclease resistance, beneficial pharmacokinetics and ease of manufacture.
  • at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 75%, such as at least 80% or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate.
  • all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate.
  • the oligonucleotide of the invention comprises both phosphorothioate internucleoside linkages and at least one phosphodiester linkage, such as 2,
  • phosphodiester linkages in addition to the phosphorodithioate linkage(s).
  • phosphodiester linkages when present, are suitably not located between contiguous DNA nucleosides in the gap region G.
  • Nuclease resistant linkages such as phosphorothioate linkages, are particularly useful in oligonucleotide regions capable of recruiting nuclease when forming a duplex with the target nucleic acid, such as region G for gapmers.
  • Phosphorothioate linkages may, however, also be useful in non-nuclease recruiting regions and/or affinity enhancing regions such as regions F and F’ for gapmers.
  • Gapmer oligonucleotides may, in some embodiments comprise one or more phosphodiester linkages in region F or F’, or both region F and F’, where all the internucleoside linkages in region G may be phosphorothioate.
  • all the internucleoside linkages in the contiguous nucleotide sequence of the oligonucleotide, or all the internucleoside linkages of the oligonucleotide are phosphorothioate linkages.
  • antisense oligonucleotides may comprise other internucleoside linkages (other than phosphodiester and phosphorothioate), for example alkyl phosphonate/methyl phosphonate internucleosides, which according to EP 2 742 135 may for example be tolerated in an otherwise DNA phosphorothioate the gap region.
  • nucleobase includes the purine (e.g. adenine and guanine) and pyrimidine (e.g. uracil, thymine and cytosine) moiety present in nucleosides and nucleotides which form hydrogen bonds in nucleic acid hybridization.
  • pyrimidine e.g. uracil, thymine and cytosine
  • nucleobase also encompasses modified nucleobases which may differ from naturally occurring
  • nucleobase refers to both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, as well as non-naturally occurring variants. Such variants are for example described in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1 .4.1.
  • the nucleobase moiety is modified by changing the purine or pyrimidine into a modifie purine or pyrimidine, such as substituted purine or substituted pyrimidine, such as a nucleobased selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo- cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil 5-thiazolo-uracil, 2-thio-uracil, 2’thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2- chloro-6-aminopurine.
  • a modifie purine or pyrimidine such as substituted purine or substituted pyrimidine, such as a nucleobased selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo
  • nucleobase moieties may be indicated by the letter code for each corresponding nucleobase moieties
  • nucleobase e.g. A, T, G, C or U, wherein each letter may optionally include modified
  • nucleobases of equivalent function are selected from A, T, G, C, and 5-methyl cytosine.
  • 5-methyl cytosine LNA nucleosides may be used.
  • modified oligonucleotide describes an oligonucleotide comprising one or more sugar- modified nucleosides and/or modified internucleoside linkages.
  • chimeric The term chimeric
  • oligonucleotide is a term that has been used in the literature to describe oligonucleotides with modified nucleosides.
  • Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A) - thymine (T)/uracil (U).
  • oligonucleotides may comprise nucleosides with modified nucleobases, for example 5-methyl cytosine is often used in place of cytosine, and as such the term complementarity encompasses Watson Crick base-paring between non-modified and modified nucleobases (see for example Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1 ).
  • % complementary refers to the proportion of nucleotides (in percent) of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which across the contiguous nucleotide sequence, are complementary to a reference sequence (e.g. a target sequence or sequence motif).
  • the percentage of complementarity is thus calculated by counting the number of aligned nucleobases that are complementary (from Watson Crick base pair) between the two sequences (when aligned with the target sequence 5’-3’ and the oligonucleotide sequence from 3’-5’), dividing that number by the total number of nucleotides in the oligonucleotide and multiplying by 100.
  • nucleobase/nucleotide which does not align is termed a mismatch. Insertions and deletions are not allowed in the calculation of % complementarity of a contiguous nucleotide sequence. It will be understood that in determining complementarity, chemical modifications of the nucleobases are disregarded as long as the functional capacity of the nucleobase to form Watson Crick base pairing is retained (e.g. 5’-methyl cytosine is considered identical to a cytosine for the purpose of calculating % identity).
  • oligonucleotide according to the invention that is fully complementary to the target nucleic acid.
  • SEQ ID NO: 7 The following is an example of an oligonucleotide (SEQ ID NO: 7) that is fully complementary to the target nucleic acid (SEQ ID NO: 17)
  • Identity refers to the proportion of nucleotides (expressed in percent) of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which across the contiguous nucleotide sequence, are identical to a reference sequence (e.g. a sequence motif).
  • the percentage of identity is thus calculated by counting the number of aligned bases that are identical (a match) between two sequences (in the contiguous nucleotide sequence of the compound of the invention and in the reference sequence), dividing that number by the total number of nucleotides in the oligonucleotide and multiplying by 100.
  • Percentage of Identity (Matches x 100)/Length of aligned region (e.g. the contiguous nucleotide sequence). Insertions and deletions are not allowed in the calculation the percentage of identity of a contiguous nucleotide sequence. It will be understood that in determining identity, chemical modifications of the nucleobases are disregarded as long as the functional capacity of the nucleobase to form Watson Crick base pairing is retained (e.g. 5- methyl cytosine is considered identical to a cytosine for the purpose of calculating % identity).
  • hybridizing or“hybridizes” as used herein is to be understood as two nucleic acid strands (e.g. an oligonucleotide and a target nucleic acid) forming hydrogen bonds between base pairs on opposite strands thereby forming a duplex.
  • the affinity of the binding between two nucleic acid strands is the strength of the hybridization. It is often described in terms of the melting temperature (T m ) defined as the temperature at which half of the oligonucleotides are duplexed with the target nucleic acid. At physiological conditions T m is not strictly proportional to the affinity (Mergny and Lacroix, 2003 , Oligonucleotides 13:515-537).
  • oligonucleotide and the target nucleic acid reflects a strong hybridization between the oligonucleotide and target nucleic acid.
  • AG° is the energy associated with a reaction where aqueous concentrations are 1 M, the pH is 7, and the temperature is 37°C.
  • the hybridization of oligonucleotides to a target nucleic acid is a spontaneous reaction and for spontaneous reactions AG° is less than zero.
  • AG° can be measured experimentally, for example, by use of the isothermal titration calorimetry (ITC) method as described in Hansen et al., 1965, Chem. Comm. 36-38 and Holdgate et al., 2005, Drug Discov Today. The skilled person will know that commercial equipment is available for AG° measurements.
  • ITC isothermal titration calorimetry
  • AG° can also be estimated numerically by using the nearest neighbor model as described by SantaLucia, 1998, Proc Natl Acad Sci USA. 95: 1460-1465 using appropriately derived thermodynamic parameters described by Sugimoto et al., 1995, Biochemistry 34:1 121 1-1 1216 and McTigue et al., 2004, Biochemistry 43:5388-5405.
  • oligonucleotides of the present invention hybridize to a target nucleic acid with estimated AG° values below -10 kcal for oligonucleotides that are 10-30 nucleotides in length.
  • the degree or strength of hybridization is measured by the standard state Gibbs free energy AG°.
  • the oligonucleotides may hybridize to a target nucleic acid with estimated AG° values below the range of -10 kcal, such as below -15 kcal, such as below -20 kcal and such as below -25 kcal for oligonucleotides that are 8-30 nucleotides in length.
  • the oligonucleotides hybridize to a target nucleic acid with an estimated AG° value of -10 to -60 kcal, such as -12 to -40, such as from -15 to -30 kcal or -16 to -27 kcal such as -18 to -25 kcal.
  • Target nucleic acid may hybridize to a target nucleic acid with estimated AG° values below the range of -10 kcal, such as below -15 kcal, such as below -20 kcal and such as below -25 kcal for oligonucleotides that are 8-30 nucleotides in length.
  • the oligonucleotides hybridize to
  • the target nucleic acid is a nucleic acid which encodes mammalian CSNK1 D and may for example be a gene, a RNA, a mRNA, and pre-mRNA, a mature mRNA or a cDNA sequence.
  • the target may therefore be referred to as a CSNK1 D target nucleic acid.
  • the oligonucleotide of the invention may for example target exon regions of a mammalian CSNK1 D, or may, for example, target intron regions in the CSNK1 D pre-mRNA (see, for example Table 1 ).
  • the target nucleic acid encodes an CSNK1 D protein, in particular mammalian
  • CSNK1 D such as human CSNK1 D (See for example Tables 2 and 3) which provides the genomic sequence, the mature mRNA and pre-mRNA sequences for human, rat and mouse and, pre-mRNA for monkey CSNK1 D target nucleic acid.
  • the target nucleic acid is selected from the group consisting of SEQ ID NO: 1 , 2, 3, 4, 5 and 6 or naturally occurring variants thereof (e.g. sequences encoding a mammalian CSNK1 D protein).
  • the target nucleic acid may, in some embodiments, be a RNA or DNA, such as messenger RNA, such as a mature mRNA or a pre-mRNA which encodes mammalian CSNK1 D protein, such as human CSNK1 D, e.g. the human pre-mRNA sequence, such as that disclosed as SEQ ID NO: 1 or human mature mRNA as disclosed in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 or naturally occurring variants thereof (e.g. sequences encoding a mammalian FNDC3B protein.
  • messenger RNA such as a mature mRNA or a pre-mRNA which encodes mammalian CSNK1 D protein, such as human CSNK1 D
  • human pre-mRNA sequence such as that disclosed as SEQ ID NO: 1 or human mature mRNA as disclosed in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 or naturally occurring variants thereof (
  • the target nucleic acid may be a cDNA or a synthetic nucleic acid derived from DNA or RNA.
  • the oligonucleotide of the invention is typically capable of inhibiting the expression of the CSNK1 D target nucleic acid in a cell which is expressing the CSNK1 D target nucleic acid.
  • the contiguous sequence of nucleobases of the oligonucleotide of the invention is typically complementary to the CSNK1 D target nucleic acid, as measured across the length of the oligonucleotide, optionally with the exception of one or two mismatches, and optionally excluding nucleotide based linker regions which may link the oligonucleotide to an optional functional group such as a conjugate, or other non-complementary terminal nucleotides (e.g. region D’ or D”).
  • rev reverse strand.
  • the genome coordinates provide the pre-mRNA sequence (genomic sequence). .
  • SEQ ID NO: 6 comprises regions of multiple NNNNs, where the sequencing has been unable to accurately refine the sequence, and a degenerate sequence is therefore included.
  • Target Sequence is complementary to the actual cynomonkey target sequence and are not therefore degenerate compounds.
  • target sequence refers to a sequence of nucleotides present in the target nucleic acid, which comprises the nucleobase sequence, which is complementary to the antisense oligonucleotide of the invention.
  • the target sequence consists of a region on the target nucleic acid, which is complementary to the contiguous nucleotide sequence of the antisense oligonucleotide of the invention. This region of the target nucleic acid may be referred to as the target nucleotide sequence.
  • the target sequence is longer than the contiguous complementary sequence of a single oligonucleotide, and may, for example represent a preferred region of the target nucleic acid which may be targeted by several oligonucleotides of the invention.
  • the antisense oligonucleotide of the invention comprises a contiguous nucleotide sequence, which is complementary to the target nucleic acid, such as a target sequence described herein.
  • the target sequence is conserved between human and monkey, in particular a sequence that is present in both SEQ ID NO: 1 and SEQ ID NO: 6. In a preferred embodiment, the target sequence is present in SEQ ID NO: 32.
  • the target sequence to which the oligonucleotide is complementary generally comprises a contiguous nucleobase sequence of at least 10 nucleotides.
  • the contiguous nucleotide sequence is between 10 to 50 nucleotides, such as 12 to 30, such as 14 to 20, such as 15 to 18 contiguous nucleotides
  • the target sequence is SEQ ID NO: 7.
  • the target sequence is SEQ ID NO: 8.
  • the target sequence is SEQ ID NO: 25.
  • the target sequence is SEQ ID NO: 26.
  • the target sequence is SEQ ID NO: 27.
  • the target sequence is SEQ ID NO: 28.
  • the target sequence is SEQ ID NO: 29.
  • the target sequence is SEQ ID NO: 30.
  • the target sequence is SEQ ID NO: 31.
  • the target sequence is SEQ ID NO: 32.
  • the target region or target sequence can be unique for the target nucleic acid (only present once).
  • the target region is repeated at least two times over the span of target nucleic acid. Repeated as encompassed by the present invention means that there are at least two identical nucleotide sequences (target regions) of at least 10, such as at least 1 1 , or at least 12, nucleotides in length which occur in the target nucleic acid at different positions. Each repeated target region is separated from the identical region by at least one nucleobase on the contiguous sequence of target nucleic acid and is positioned at different and non-overlapping positions within the target nucleic acid.
  • Target Cells a nucleotide sequences
  • a“target cell” as used herein refers to a cell which is expressing the target nucleic acid.
  • the target cell may be in vivo or in vitro.
  • the target cell is a mammalian cell such as a rodent cell, such as a mouse cell or a rat cell, or a primate cell such as a monkey cell or a human cell.
  • the target cell expresses CSNK1 D mRNA, such as the CSNK1 D pre-mRNA or CSNK1 D mature mRNA.
  • CSNK1 D mRNA such as the CSNK1 D pre-mRNA or CSNK1 D mature mRNA.
  • the poly A tail of CSNK1 D mRNA is typically disregarded for antisense oligonucleotide targeting.
  • naturally occurring variant refers to variants of CSNK1 D gene or transcripts which originate from the same genetic loci as the target nucleic acid and is a directional transcript from the same chromosomal position and direction as the target nucleic acid, but may differ for example, by virtue of degeneracy of the genetic code causing a multiplicity of codons encoding the same amino acid, or due to alternative splicing of pre-mRNA, or the presence of
  • the oligonucleotide of the invention may therefore target the target nucleic acid and naturally occurring variants thereof.
  • the naturally occurring variants have at least 95% such as at least 98% or at least 99% homology to a mammalian CSNK1 D target nucleic acid, such as a target nucleic acid selected form the group consisting of SEQ ID NO 1 , 2, 3, 4, 5 and 6.
  • modulation of expression is to be understood as an overall term for an antisense oligonucleotide’s ability to alter the amount of CSNK1 D when compared to the amount of CSNK1 D before administration of the antisense oligonucleotide.
  • modulation of expression may be determined by reference to a control experiment. It is generally understood that the control is an individual or target cell treated with a saline composition or an individual or target cell treated with a non-targeting oligonucleotide (mock).
  • a modulation according to the present invention shall be understood as an antisense oligonucleotide’s ability to inhibit, down-regulate, reduce, suppress, remove, stop, block, prevent, lessen, lower, avoid or terminate expression of mammalian CSNK1 D, e.g. by degradation of mRNA or blockage of transcription.
  • a high affinity modified nucleoside is a modified nucleotide which, when incorporated into the oligonucleotide enhances the affinity of the oligonucleotide for its complementary target, for example as measured by the melting temperature (T m ).
  • a high affinity modified nucleoside of the present invention preferably result in an increase in melting temperature between +0.5 to +12°C, more preferably between +1.5 to +10°C and most preferably between+3 to +8°C per modified nucleoside.
  • Numerous high affinity modified nucleosides are known in the art and include for example, many 2’ substituted nucleosides as well as locked nucleic acids (LNA) (see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213).
  • the oligomer of the invention may comprise one or more nucleosides which have a modified sugar moiety, i.e. a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA.
  • nucleosides with modification of the ribose sugar moiety have been made, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or nuclease resistance.
  • Such modifications include those where the ribose ring structure is modified, e.g. by
  • HNA hexose ring
  • LNA ribose ring
  • UPA unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons
  • Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids (WO201 1/017521 ) or tricyclic nucleic acids (WO2013/154798). Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of peptide nucleic acids (PNA), or morpholino nucleic acids.
  • PNA peptide nucleic acids
  • Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2’-OH group naturally found in DNA and RNA nucleosides. Substituents may, for example be introduced at the 2’, 3’, 4’ or 5’ positions.
  • Nucleosides with modified sugar moieties also include 2’ modified nucleosides, such as 2’ substituted nucleosides. Indeed, much focus has been spent on developing 2’ substituted nucleosides, and numerous 2’ substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides, such as enhanced nucleoside resistance and enhanced affinity.
  • a 2’ sugar modified nucleoside is a nucleoside which has a substituent other than H or -OH at the 2’ position (2’ substituted nucleoside) or comprises a 2’ linked biradicle capable of forming a bridge between the 2’ carbon and a second carbon in the ribose ring, such as LNA (2’ - 4’ biradicle bridged) nucleosides.
  • 2’ substituted modified nucleosides are 2’-0- alkyl-RNA, 2’-0-methyl-RNA, 2’-alkoxy-RNA, 2’-0-methoxyethyl-RNA (MOE), 2’-amino-DNA, 2’- Fluoro-RNA, and 2’-F-ANA nucleoside.
  • MOE methoxyethyl-RNA
  • 2’-amino-DNA 2’- Fluoro-RNA
  • 2’-F-ANA nucleoside examples of 2’ substituted modified nucleosides.
  • LNA Locked Nucleic Acid Nucleosides
  • A“LNA nucleoside” is a 2’-modified nucleoside which comprises a biradical linking the C2’ and C4’ of the ribose sugar ring of said nucleoside (also referred to as a“2’- 4’ bridge”), which restricts or locks the conformation of the ribose ring.
  • These nucleosides are also termed bridged nucleic acid or bicyclic nucleic acid (BNA) in the literature.
  • BNA bicyclic nucleic acid
  • the locking of the conformation of the ribose is associated with an enhanced affinity of hybridization (duplex stabilization) when the LNA is incorporated into an oligonucleotide for a complementary RNA or DNA molecule. This can be routinely determined by measuring the melting temperature of the
  • Non limiting, exemplary LNA nucleosides are disclosed in WO 99/014226, WO 00/66604, WO 98/039352 , WO 2004/046160, WO 00/047599, WO 2007/134181 , WO 2010/077578, WO 2010/036698, WO 2007/090071 , WO 2009/006478, WO 201 1/156202, WO 2008/154401 , WO 2009/067647, WO 2008/150729, Morita et al., Bioorganic & Med.Chem. Lett. 12, 73-76, Seth et al. J. Org. Chem. 2010, Vol 75(5) pp.
  • the 2’-4’ bridge comprises 2 to 4 bridging atoms and is in particular of formula -X-Y-, X being linked to C4’ and Y linked to C2’,
  • X is oxygen, sulfur,
  • R a and R b are independently selected from hydrogen, halogen, hydroxyl, cyano,
  • substituted alkyl, substituted alkenyl, substituted alkynyl, substituted alkoxy and substituted methylene are alkyl, alkenyl, alkynyl and methylene substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl, heterocylyl, aryl and heteroaryl;
  • X a is oxygen, sulfur or -NR C ;
  • R c , R d and R e are independently selected from hydrogen and alkyl
  • n 1 , 2 or 3.
  • Y is -CR a R b -, -CR a R b -CR a R b - or -CR a R b CR a R b CR a R b -, particularly -CH 2 -CHCH 3 -, -CHCH 3 -CH 2 -, -CH 2 -CH 2 - or -CH 2 -CH 2 -CH 2 -CH 2 -.
  • R a and R b are independently selected from the group consisting of hydrogen, halogen, hydroxyl, alkyl and alkoxyalkyl, in particular hydrogen, halogen, alkyl and alkoxyalkyl.
  • R a and R b are independently selected from the group consisting of hydrogen, fluoro, hydroxyl, methyl and -CH 2 -0-CH 3 , in particular hydrogen, fluoro, methyl and -CH 2 -0-CH 3 .
  • one of R a and R b of -X-Y- is as defined above and the other ones are all hydrogen at the same time.
  • R a is hydrogen or alkyl, in particular hydrogen or methyl.
  • R b is hydrogen or or alkyl, in particular hydrogen or methyl.
  • R a and R b are hydrogen.
  • R a and R b are hydrogen.
  • one of R a and R b is methyl and the other one is hydrogen.
  • R a and R b are both methyl at the same time.
  • -X-Y- is -0-CH 2 -, -S-CH 2 -, -S-CH(CH 3 )-, -NH-CH 2 -, -
  • -X-Y- is -0-CR a R b - wherein R a and R b are independently selected from the group consisting of hydrogen, alkyl and alkoxyalkyl, in particular hydrogen, methyl and -CH 2 -0-CH 3 .
  • -X-Y- is -0-CH 2 - or -0-CH(CH 3 )-, particularly -0-CH 2 -.
  • the 2’- 4’ bridge may be positioned either below the plane of the ribose ring (beta-D- configuration), or above the plane of the ring (alpha-L- configuration), as illustrated in formula (A) and formula (B) respectively.
  • the LNA nucleoside according to the invention is in particular of formula (A) or (B)
  • W is oxygen, sulfur, -N(R a )- or -CR a R b -, in particular oxygen;
  • B is a nucleobase or a modified nucleobase
  • Z is an internucleoside linkage to an adjacent nucleoside or a 5'-terminal group
  • Z * is an internucleoside linkage to an adjacent nucleoside or a 3'-terminal group
  • R 1 , R 2 , R 3 , R 5 and R 5* are independently selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkyl, azido, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl, formyl and aryl; and
  • X, Y, R a and R b are as defined above.
  • R a is hydrogen or alkyl, in particular hydrogen or methyl.
  • R b is hydrogen or alkyl, in particular hydrogen or methyl.
  • one or both of R a and R b are hydrogen.
  • only one of R a and R b is hydrogen.
  • one of R a and R b is methyl and the other one is hydrogen.
  • R a and R b are both methyl at the same time.
  • R a is hydrogen or alkyl, in particular hydrogen or methyl.
  • R b is hydrogen or alkyl, in particular hydrogen or methyl.
  • one or both of R a and R b are hydrogen.
  • only one of R a and R b is hydrogen.
  • one of R a and R b is methyl and the other one is hydrogen.
  • R a and R b are both methyl at the same time.
  • R a is hydrogen or alkyl, in particular hydrogen or methyl.
  • R b is hydrogen or alkyl, in particular hydrogen or methyl.
  • one or both of R a and R b are hydrogen.
  • only one of R a and R b is hydrogen.
  • one of R a and R b is methyl and the other one is hydrogen.
  • R a and R b are both methyl at the same time.
  • R 1 , R 2 , R 3 , R 5 and R 5* are independently selected from hydrogen and alkyl, in particular hydrogen and methyl.
  • R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • R 1 , R 2 , R 3 are all hydrogen at the same time, one of R 5 and R 5* is hydrogen and the other one is as defined above, in particular alkyl, more particularly methyl.
  • R 5 and R 5* are independently selected from hydrogen, halogen, alkyl, alkoxyalkyl and azido, in particular from hydrogen, fluoro, methyl, methoxyethyl and azido.
  • one of R 5 and R 5* is hydrogen and the other one is alkyl, in particular methyl, halogen, in particular fluoro, alkoxyalkyl, in particular methoxyethyl or azido; or R 5 and R 5* are both hydrogen or halogen at the same time, in particular both hydrogen of fluoro at the same time.
  • W can advantageously be oxygen, and -X-Y- advantageously -0-CH 2 -.
  • -X-Y- is -0-CH 2 -
  • W is oxygen
  • R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • -X-Y- is -S-CH 2 -
  • W is oxygen
  • R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • -X-Y- is -NH-CH 2 -
  • W is oxygen
  • R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • -X-Y- is -0-CH 2 CH 2 - or -OCH 2 CH 2 CH 2 -
  • W is oxygen
  • R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • LNA nucleosides are disclosed in WO 00/047599 and Morita et a!., Bioorganic & Med.Chem. Lett. 12, 73-76, which are hereby incorporated by reference, and include what are commonly known in the art as 2’-0-4’C-ethylene bridged nucleic acids (ENA).
  • -X-Y- is -0-CH 2 -
  • W is oxygen
  • R 1 , R 2 , R 3 are all hydrogen at the same time
  • one of R 5 and R 5* is hydrogen and the other one is not hydrogen, such as alkyl, for example methyl.
  • Such 5’ substituted LNA nucleosides are disclosed in WO 2007/134181 which is hereby incorporated by reference.
  • -X-Y- is -0-CR a R b -, wherein one or both of R a and R b are not hydrogen, in particular alkyl such as methyl, W is oxygen, R 1 , R 2 , R 3 are all hydrogen at the same time, one of R 5 and R 5* is hydrogen and the other one is not hydrogen, in particular alkyl, for example methyl.
  • R a and R b are not hydrogen, in particular alkyl such as methyl
  • W is oxygen
  • R 1 , R 2 , R 3 are all hydrogen at the same time
  • one of R 5 and R 5* is hydrogen and the other one is not hydrogen, in particular alkyl, for example methyl.
  • Such bis modified LNA nucleosides are disclosed in WO 2010/077578 which is hereby incorporated by reference.
  • -X-Y- is -0-CHR a -
  • W is oxygen
  • R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • R a is in particular CrC 6 alkyl, such as methyl.
  • -X-Y- is -0-CH(CH 2 -0-CH 3 )- (“2’ O- methoxyethyl bicyclic nucleic acid”, Seth et al. J. Org. Chem. 2010, Vol 75(5) pp. 1569-81 ).
  • -X-Y- is -0-CH(CH 2 CH 3 )- (“2’O-ethyl bicyclic nucleic acid”, Seth at al., J. Org. Chem. 2010, Vol 75(5) pp. 1569-81 ).
  • -X-Y- is -0-CH(CH 2 -0-CH 3 )-
  • W is oxygen
  • R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • LNA nucleosides are also known in the art as cyclic MOEs (cMOE) and are disclosed in WO 2007/090071 .
  • -X-Y- is -0-CH(CH 3 )-.
  • -X-Y- is -0-CH 2.
  • 0-CH 2 - (Seth et a!., J. Org. Chem 2010 op. cit.)
  • -X-Y- is -0-CH(CH 3 )-
  • W is oxygen and R 1 ,
  • R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • Such 6’-methyl LNA nucleosides are also known in the art as cET nucleosides, and may be either (S)-cET or (R)-cET diastereoisomers, as disclosed in WO 2007/090071 (beta-D) and WO 2010/036698 (alpha-L) which are both hereby incorporated by reference.
  • -X-Y- is -0-CR a R b -, wherein neither R a nor R b is hydrogen, W is oxygen and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • R a and R b are both alkyl at the same time, in particular both methyl at the same time.
  • -X-Y- is -S-CHR a -
  • W is oxygen and R 1 , R 2 ,
  • R 3 , R 5 and R 5* are all hydrogen at the same time.
  • Such 6’-substituted thio LNA nucleosides are disclosed in WO 201 1/156202 which is hereby incorporated by reference.
  • R a is alkyl, in particular methyl.
  • R a and R b are advantagesously independently selected from hydrogen, halogen, alkyl and alkoxyalkyl, in particular hydrogen, methyl, fluoro and methoxymethyl.
  • R a and R b are in particular both hydrogen or methyl at the same time or one of R a and R b is hydrogen and the other one is methyl.
  • Such vinyl carbo LNA nucleosides are disclosed in WO 2008/154401 and WO 2009/067647 which are both hereby incorporated by reference.
  • -X-Y- is -N(OR a )-CH 2 -
  • W is oxygen
  • R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • R a is alkyl such as methyl.
  • -X-Y- is -0-N(R a )-, -N(R a )-0-, -NR a -CR a R b -CR a R b - or -NR a -CR a R b -, W is oxygen and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • R a and R b are advantagesously independently selected from hydrogen, halogen, alkyl and alkoxyalkyl, in particular hydrogen, methyl, fluoro and methoxymethyl.
  • R a is alkyl, such as methyl
  • R b is hydrogen or methyl, in particular hydrogen.
  • -X-Y- is -0-N(CH 3 )- (Seth et a!., J. Org. Chem 2010 op. cit.).
  • R 5 and R 5* are both hydrogen at the same time.
  • one of R 5 and R 5* is hydrogen and the other one is alkyl, such as methyl.
  • R 1 , R 2 and R 3 can be in particular hydrogen and -X-Y- can be in particular -0-CH 2 - or -0-CHC(R a ) 3 -, such as -0-CH(CH 3 )-.
  • -X-Y- is -CR a R b -0-CR a R b -, such as -CH 2 -0-CH 2 -
  • W is oxygen and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • R a can be in particular alkyl such as methyl, R b hydrogen or methyl, in particular hydrogen.
  • LNA nucleosides are also known as conformationally restricted nucleotides (CRNs) and are disclosed in WO 2013/036868 which is hereby incorporated by reference.
  • -X-Y- is -0-CR a R b -0-CR a R b -, such as -0-CH 2 -0- CH 2 -
  • W is oxygen and R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen at the same time.
  • R a and R b are advantageously independently selected from hydrogen, halogen, alkyl and alkoxyalkyl, in particular hydrogen, methyl, fluoro and methoxymethyl.
  • R a can be in particular alkyl such as methyl, R b hydrogen or methyl, in particular hydrogen.
  • LNA nucleosides are also known as COC nucleotides and are disclosed in Mitsuoka et a!., Nucleic Acids Research 2009, 37(4), 1225-1238, which is hereby incorporated by reference. It will be recognized that, unless specified, the LNA nucleosides may be in the beta-D or alpha-L stereoisoform.
  • LNA nucleosides are beta-D-oxy-LNA, 6’-methyl-beta-D-oxy LNA such as (S)-6’- methyl-beta-D-oxy-LNA (ScET) and ENA.
  • one of the starting materials or compounds of the invention contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps
  • appropriate protecting groups as described e.g. in“Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wuts, 3rd Ed., 1999, Wiley, New York
  • Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
  • protecting groups are tert-butoxycarbonyl (Boc), 9-fluorenylmethyl carbamate (Fmoc), 2-trimethylsilylethyl carbamate (Teoc), carbobenzyloxy (Cbz) and p- methoxybenzyloxycarbonyl (Moz).
  • the compounds described herein can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
  • asymmetric carbon atom means a carbon atom with four different substituents. According to the Cahn-lngold-Prelog Convention an asymmetric carbon atom can be of the“R” or“S” configuration.
  • alkyl signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, particularly a straight or branched-chain alkyl group with 1 to 6 carbon atoms and more particularly a straight or branched-chain alkyl group with 1 to 4 carbon atoms.
  • straight-chain and branched-chain C C 8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls and the isomeric octyls, particularly methyl, ethyl, propyl, butyl and pentyl.
  • Particular examples of alkyl are methyl, ethyl and propyl.
  • cycloalkyl signifies a cycloalkyl ring with 3 to 8 carbon atoms and particularly a cycloalkyl ring with 3 to 6 carbon atoms.
  • cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, more particularly cyclopropyl and cyclobutyl.
  • a particular example of“cycloalkyl” is cyclopropyl.
  • alkoxy signifies a group of the formula alkyl-O- in which the term "alkyl” has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.butoxy and tert.butoxy.
  • Particular“alkoxy” are methoxy and ethoxy.
  • Methoxyethoxy is a particular example of“alkoxyalkoxy”.
  • alkenyl signifies a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 8, preferably up to 6, particularly preferred up to 4 carbon atoms.
  • alkenyl groups are ethenyl, 1 -propenyl, 2-propenyl, isopropenyl, 1 - butenyl, 2-butenyl, 3-butenyl and isobutenyl.
  • alkynyl alone or in combination, signifies a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 8, preferably up to 6, particularly preferred up to 4 carbon atoms.
  • halogen or“halo”, alone or in combination, signifies fluorine, chlorine, bromine or iodine and particularly fluorine, chlorine or bromine, more particularly fluorine.
  • haloalkyl denotes an alkyl group substituted with at least one halogen, particularly substituted with one to five halogens, particularly one to three halogens.
  • haloalkyl include monofluoro-, difluoro- or trifluoro-methyl, -ethyl or - propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl or trifluoromethyl. Fluoromethyl, difluoromethyl and trifluoromethyl are particular“haloalkyl”.
  • halocycloalkyl denotes a cycloalkyl group as defined above substituted with at least one halogen, particularly substituted with one to five halogens, particularly one to three halogens.
  • Particular example of“halocycloalkyl” are halocyclopropyl, in particular fluorocyclopropyl, difluorocyclopropyl and trifluorocyclopropyl.
  • carbonyl alone or in combination, signifies the -C(O)- group.
  • amino alone or in combination, signifies the primary amino group (-NH 2 ), the secondary amino group (-NH-), or the tertiary amino group (-N-).
  • alkylamino alone or in combination, signifies an amino group as defined above substituted with one or two alkyl groups as defined above.
  • sulfonyl alone or in combination, means the -S0 2 group.
  • cabamido alone or in combination, signifies the -NH-C(0)-NH 2 group.
  • aryl denotes a monovalent aromatic carbocyclic mono- or bicyclic ring system comprising 6 to 10 carbon ring atoms, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl.
  • substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl.
  • Examples of aryl include phenyl and naphthyl, in particular phenyl.
  • heteroaryl denotes a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1 , 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl.
  • heteroaryl examples include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl,
  • benzoisothiazolyl benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, carbazolyl or acridinyl.
  • heterocyclyl signifies a monovalent saturated or partly unsaturated mono- or bicyclic ring system of 4 to 12, in particular 4 to 9 ring atoms, comprising 1 , 2,3 or 4 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl.
  • Examples for monocyclic saturated heterocyclyl are azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1 ,1 -dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl.
  • bicyclic saturated heterocycloalkyl examples include 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2.1 ]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza- bicyclo[3.3.1]nonyl, or 3-thia-9-aza-bicyclo[3.3.1]nonyl.
  • Examples for partly unsaturated heterocycloalkyl are dihydrofuryl, imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl or dihydropyranyl.
  • salts refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable.
  • the salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, particularly hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein.
  • salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts.
  • Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins.
  • the compound of formula (I) can also be present in the form of zwitterions.
  • Particularly preferred pharmaceutically acceptable salts of compounds of formula (I) are the salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and methanesulfonic acid.
  • protecting group signifies a group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site.
  • Protecting groups can be removed.
  • Exemplary protecting groups are amino-protecting groups, carboxy-protecting groups or hydroxy-protecting groups.
  • Nuclease mediated degradation refers to an oligonucleotide capable of mediating degradation of a complementary nucleotide sequence when forming a duplex with such a sequence.
  • the oligonucleotide may function via nuclease mediated degradation of the target nucleic acid, where the oligonucleotides of the invention are capable of recruiting a nuclease, particularly and endonuclease, preferably endoribonuclease (RNase), such as RNase H.
  • RNase endoribonuclease
  • oligonucleotide designs which operate via nuclease mediated mechanisms are oligonucleotides which typically comprise a region of at least 5 or 6 DNA nucleosides and are flanked on one side or both sides by affinity enhancing nucleosides, for example gapmers, headmers and tailmers.
  • the RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when in a duplex with a complementary RNA molecule.
  • WO01/23613 provides in vitro methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH.
  • an oligonucleotide is deemed capable of recruiting RNase H if it, when provided with a complementary target nucleic acid sequence, has an initial rate, as measured in pmol/l/min, of at least 5%, such as at least 10% or more than 20% of the of the initial rate determined when using a oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Example 91 - 95 of WO01/23613 (hereby incorporated by reference).
  • recombinant human RNase H1 is available from Lubio Science GmbH, Lucerne, Switzerland.
  • the antisense oligonucleotide of the invention, or contiguous nucleotide sequence thereof may be a gapmer.
  • the antisense gapmers are commonly used to inhibit a target nucleic acid via RNase H mediated degradation.
  • a gapmer oligonucleotide comprises at least three distinct structural regions a 5’-flank, a gap and a 3’-flank, F-G-F’ in the‘5 -> 3’ orientation.
  • The“gap” region (G) comprises a stretch of contiguous DNA nucleotides which enable the oligonucleotide to recruit RNase H.
  • the gap region is flanked by a 5’ flanking region (F) comprising one or more sugar modified nucleosides, advantageously high affinity sugar modified nucleosides, and by a 3’ flanking region (F’) comprising one or more sugar modified nucleosides, advantageously high affinity sugar modified nucleosides.
  • the one or more sugar modified nucleosides in region F and F’ enhance the affinity of the oligonucleotide for the target nucleic acid (i.e. are affinity enhancing sugar modified nucleosides).
  • the one or more sugar modified nucleosides in region F and F’ are 2’ sugar modified nucleosides, such as high affinity 2’ sugar modifications, such as independently selected from LNA and 2’-MOE.
  • the 5’ and 3’ most nucleosides of the gap region are DNA nucleosides, and are positioned adjacent to a sugar modified nucleoside of the 5’ (F) or 3’ (F’) region respectively.
  • the flanks may further defined by having at least one sugar modified nucleoside at the end most distant from the gap region, i.e. at the 5’ end of the 5’ flank and at the 3’ end of the 3’ flank.
  • Regions F-G-F’ form a contiguous nucleotide sequence.
  • Antisense oligonucleotides of the invention, or the contiguous nucleotide sequence thereof, may comprise a gapmer region of formula F-G-F’.
  • the overall length of the gapmer design F-G-F’ may be, for example 12 to 32 nucleosides, such as 13 to 24, such as 14 to 22 nucleosides, Such as from 14 to17, such as 16 to18 nucleosides.
  • the gapmer oligonucleotide of the present invention can be represented by the following formulae:
  • Fi_ 8 -G 5-i 6 -F’i- 8 such as
  • Regions F, G and F’ are further defined below and can be incorporated into the F-G-F’ formula.
  • Region G (gap region) of the gapmer is a region of nucleosides which enables the
  • oligonucleotide to recruit RNaseH such as human RNase H1
  • RNaseH typically DNA nucleosides
  • RNaseH is a cellular enzyme which recognizes the duplex between DNA and RNA, and enzymatically cleaves the RNA molecule.
  • Suitably gapmers may have a gap region (G) of at least 5 or 6 contiguous DNA nucleosides, such as 5 - 16 contiguous DNA nucleosides, such as 6 - 15 contiguous DNA nucleosides, such as 7-14 contiguous DNA nucleosides, such as 8 - 12 contiguous DNA nucleotides, such as 8 - 12 contiguous DNA nucleotides in length.
  • the gap region G may, in some embodiments consist of 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15 or 16 contiguous DNA nucleosides.
  • Cytosine (C) DNA in the gap region may in some instances be methylated, such residues are either annotated as 5-methyl-cytosine ( me C or with an e instead of a c). Methylation of Cytosine DNA in the gap is advantageous if eg dinucleotides are present in the gap to reduce potential toxicity, the modification does not have significant impact on efficacy of the oligonucleotides.
  • the gap region G may consist of 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15 or 16 contiguous phosphorothioate linked DNA nucleosides. In some embodiments, all
  • internucleoside linkages in the gap are phosphorothioate linkages.
  • Modified nucleosides which allow for RNaseH recruitment when they are used within the gap region include, for example, alpha-L-LNA, C4’ alkylated DNA (as described in PCT/EP2009/050349 and Vester et al., Bioorg. Med. Chem. Lett. 18 (2008) 2296 - 2300, both incorporated herein by reference), arabinose derived nucleosides like ANA and 2'F- ANA (Mangos et al. 2003 J. AM. CHEM. SOC.
  • UNA unlocked nucleic acid
  • the modified nucleosides used in such gapmers may be nucleosides which adopt a 2’ endo (DNA like) structure when introduced into the gap region, i.e. modifications which allow for RNaseH recruitment).
  • the DNA Gap region (G) described herein may optionally contain 1 to 3 sugar modified nucleosides which adopt a 2’ endo (DNA like) structure when introduced into the gap region. Region G -“Gap-breaker”
  • Gap-breaker oligonucleotides retain sufficient region of DNA nucleosides within the gap region to allow for RNaseH recruitment.
  • the ability of gapbreaker oligonucleotide design to recruit RNaseH is typically sequence or even compound specific - see Rukov et al. 2015 Nucl. Acids Res. Vol.
  • Modified nucleosides used within the gap region of gap-breaker oligonucleotides may for example be modified nucleosides which confer a 3’endo confirmation, such 2’ -O-methyl (OMe) or 2’-0- MOE (MOE) nucleosides, or beta-D LNA nucleosides (the bridge between C2’ and C4’ of the ribose sugar ring of a nucleoside is in the beta conformation), such as beta-D-oxy LNA or ScET nucleosides.
  • the gap region of gap-breaker or gap- disrupted gapmers have a DNA nucleosides at the 5’ end of the gap (adjacent to the 3’ nucleoside of region F), and a DNA nucleoside at the 3’ end of the gap (adjacent to the 5’ nucleoside of region F’).
  • Gapmers which comprise a disrupted gap typically retain a region of at least 3 or 4 contiguous DNA nucleosides at either the 5’ end or 3’ end of the gap region.
  • Exemplary designs for gap-breaker oligonucleotides include
  • region G is within the brackets [D n -E r - D m ], D is a contiguous sequence of DNA nucleosides, E is a modified nucleoside (the gap-breaker or gap-disrupting nucleoside), and F and F’ are the flanking regions as defined herein, and with the proviso that the overall length of the gapmer regions F-G-F’ is at least 12, such as at least 14 nucleotides in length.
  • region G of a gap disrupted gapmer comprises at least 6 DNA nucleosides, such as 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15 or 16 DNA nucleosides.
  • the DNA nucleosides may be contiguous or may optionally be interspersed with one or more modified nucleosides, with the proviso that the gap region G is capable of mediating RNaseH recruitment.
  • Region F is positioned immediately adjacent to the 5’ DNA nucleoside of region G.
  • the 3’ most nucleoside of region F is a sugar modified nucleoside, such as a high affinity sugar modified nucleoside, for example a 2’ substituted nucleoside, such as a MOE nucleoside, or an LNA nucleoside.
  • Region F’ is positioned immediately adjacent to the 3’ DNA nucleoside of region G.
  • the 5’ most nucleoside of region F’ is a sugar modified nucleoside, such as a high affinity sugar modified nucleoside, for example a 2’ substituted nucleoside, such as a MOE nucleoside, or an LNA nucleoside.
  • Region F is 1 -8 contiguous nucleotides in length, such as 2-6, such as 3-4 contiguous nucleotides in length.
  • the 5’ most nucleoside of region F is a sugar modified nucleoside.
  • the two 5’ most nucleoside of region F are sugar modified nucleoside.
  • the 5’ most nucleoside of region F is an LNA nucleoside.
  • the two 5’ most nucleoside of region F are LNA nucleosides.
  • the two 5’ most nucleoside of region F are 2’ substituted nucleoside nucleosides, such as two 3’ MOE nucleosides.
  • the 5’ most nucleoside of region F is a 2’ substituted nucleoside, such as a MOE nucleoside.
  • Region F’ is 2-8 contiguous nucleotides in length, such as 3-6, such as 4-5 contiguous nucleotides in length.
  • the 3’ most nucleoside of region F’ is a sugar modified nucleoside.
  • the two 3’ most nucleoside of region F’ are sugar modified nucleoside.
  • the two 3’ most nucleoside of region F’ are LNA nucleosides.
  • the 3’ most nucleoside of region F’ is an LNA nucleoside.
  • the two 3’ most nucleoside of region F’ are 2’ substituted nucleoside nucleosides, such as two 3’ MOE nucleosides.
  • the 3’ most nucleoside of region F’ is a 2’ substituted nucleoside, such as a MOE nucleoside.
  • region F or F is one, it is advantageously an LNA nucleoside.
  • region F and F’ independently consists of or comprises a contiguous sequence of sugar modified nucleosides.
  • nucleosides of region F may be independently selected from 2’-0-alkyl-RNA units, 2’-0-methyl- RNA, 2’-amino-DNA units, 2’-fluoro-DNA units, 2’-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2’-fluoro-ANA units.
  • region F and F’ independently comprises both LNA and a 2’ substituted modified nucleosides (mixed wing design).
  • region F and F’ consists of only one type of sugar modified nucleosides, such as only MOE or only beta-D-oxy LNA or only ScET. Such designs are also termed uniform flanks or uniform gapmer design.
  • all the nucleosides of region F or F’, or F and F’ are LNA nucleosides, such as independently selected from beta-D-oxy LNA, ENA or ScET nucleosides.
  • region F consists of 1 -5, such as 2-4, such as 3-4 such as 1 , 2, 3, 4 or 5 contiguous LNA nucleosides.
  • all the nucleosides of region F and F’ are beta-D-oxy LNA nucleosides.
  • nucleosides of region F or F’, or F and F’ are 2’ substituted nucleosides, such as OMe or MOE nucleosides.
  • region F consists of 1 ,
  • flanking regions can consist of 2’ substituted nucleosides, such as OMe or MOE nucleosides.
  • the 3’ (F’) flanking region that consists 2’ substituted nucleosides, such as OMe or MOE nucleosides whereas the 5’ (F) flanking region comprises at least one LNA nucleoside, such as beta-D-oxy LNA nucleosides or cET nucleosides.
  • all the modified nucleosides of region F and F’ are LNA nucleosides, such as independently selected from beta-D-oxy LNA, ENA or ScET nucleosides, wherein region F or F’, or F and F’ may optionally comprise DNA nucleosides (an alternating flank, see definition of these for more details).
  • all the modified nucleosides of region F and F’ are beta-D-oxy LNA nucleosides, wherein region F or F’, or F and F’ may optionally comprise DNA nucleosides (an alternating flank, see definition of these for more details).
  • the 5’ most and the 3’ most nucleosides of region F and F’ are LNA nucleosides, such as beta-D-oxy LNA nucleosides or ScET nucleosides.
  • the internucleoside linkage between region F and region G is a phosphorothioate internucleoside linkage. In some embodiments, the internucleoside linkage between region F’ and region G is a phosphorothioate internucleoside linkage. In some embodiments, the internucleoside linkages between the nucleosides of region F or F’, F and F’ are phosphorothioate internucleoside linkages.
  • An LNA gapmer is a gapmer wherein either one or both of region F and F’ comprises or consists of LNA nucleosides.
  • a beta-D-oxy gapmer is a gapmer wherein either one or both of region F and F’ comprises or consists of beta-D-oxy LNA nucleosides.
  • the LNA gapmer is of formula: [LNA ⁇ -s-tregion G] -[LNA] ⁇ , wherein region G is as defined in the Gapmer region G definition.
  • a MOE gapmers is a gapmer wherein regions F and F’ consist of MOE nucleosides.
  • the MOE gapmer is of design [MOE ⁇ -s- Ftegion G]-[MOE] 1-8 , such as [MOE] 2-7 - [Region G] 5 -i6-[MOE] 2 -7, such as [MOE] 3.6 -[Region G]-[MOE] 3.6 , wherein region G is as defined in the Gapmer definition.
  • MOE gapmers with a 5-10-5 design have been widely used in the art.
  • a mixed wing gapmer is an LNA gapmer wherein one or both of region F and F’ comprise a 2’ substituted nucleoside, such as a 2’ substituted nucleoside independently selected from the group consisting of 2’-0-alkyl-RNA units, 2’-0-methyl-RNA, 2’-amino-DNA units, 2’-fluoro-DNA units, 2’-alkoxy-RNA, MOE units, arabino nucleic acid (ANA) units and 2’-fluoro-ANA units, such as a MOE nucleosides.
  • a 2’ substituted nucleoside independently selected from the group consisting of 2’-0-alkyl-RNA units, 2’-0-methyl-RNA, 2’-amino-DNA units, 2’-fluoro-DNA units, 2’-alkoxy-RNA, MOE units, arabino nucleic acid (ANA) units and 2’-fluoro-ANA units, such as a MOE nucleosides.
  • region F and F’, or both region F and F’ comprise at least one LNA nucleoside
  • the remaining nucleosides of region F and F’ are independently selected from the group consisting of MOE and LNA.
  • at least one of region F and F’, or both region F and F’ comprise at least two LNA nucleosides
  • the remaining nucleosides of region F and F’ are independently selected from the group consisting of MOE and LNA.
  • one or both of region F and F’ may further comprise one or more DNA nucleosides.
  • Flanking regions may comprise both LNA and DNA nucleoside and are referred to as
  • alternating flanks as they comprise an alternating motif of LNA-DNA-LNA nucleosides.
  • flank gapmers comprising such alternating flanks are referred to as "alternating flank gapmers".
  • “Alternative flank gapmers” are thus LNA gapmer oligonucleotides where at least one of the flanks (F or F’) comprises DNA in addition to the LNA nucleoside(s).
  • at least one of region F or F’, or both region F and F’ comprise both LNA nucleosides and DNA nucleosides.
  • the flanking region F or F’, or both F and F’ comprise at least three nucleosides, wherein the 5’ and 3’ most nucleosides of the F and/or F’ region are LNA nucleosides.
  • Oligonucleotides with alternating flanks are LNA gapmer oligonucleotides where at least one of the flanks (F or F’) comprises DNA in addition to the LNA nucleoside(s).
  • at least one of region F or F’, or both region F and F’ comprise both LNA nucleosides and DNA nucleosides.
  • the flanking region F or F’, or both F and F’ comprise at least three nucleosides, wherein the 5’ and 3’ most nucleosides of the F and/or F’ region are LNA nucleosides.
  • region F or F’, or both region F and F’ comprise both LNA nucleosides and DNA nucleosides.
  • the flanking region F or F’, or both F and F’ comprise at least three nucleosides, wherein the 5’ and 3’ most nucleosides of the F or F’ region are LNA nucleosides, and the.
  • Flanking regions which comprise both LNA and DNA nucleoside are referred to as alternating flanks, as they comprise an alternating motif of LNA- DNA-LNA nucleosides. Alternating flank LNA gapmers are disclosed in WO2016/127002.
  • An alternating flank region may comprise up to 3 contiguous DNA nucleosides, such as 1 to 2 or 1 or 2 or 3 contiguous DNA nucleosides.
  • the alternating flak can be annotated as a series of integers, representing a number of LNA nucleosides (L) followed by a number of DNA nucleosides (D), for example
  • flanks in oligonucleotide designs these will often be represented as numbers such that 2-2-1 represents 5’ [L] 2 -[D] 2 -[L] 3’, and 1 -1 -1 -1 -1 represents 5’ [L]-[D]-[L]-[D]-[L] 3’.
  • the length of the flank (region F and F’) in oligonucleotides with alternating flanks may independently be 3 to 10 nucleosides, such as 4 to 8, such as 5 to 6 nucleosides, such as 4, 5, 6 or 7 modified
  • flanks in the gapmer oligonucleotide are alternating while the other is constituted of LNA nucleotides. It may be advantageous to have at least two LNA nucleosides at the 3’ end of the 3’ flank (F’), to confer additional exonuclease resistance.
  • the oligonucleotide of the invention may in some embodiments comprise or consist of the contiguous nucleotide sequence of the oligonucleotide which is complementary to the target nucleic acid, such as the gapmer F-G-F’, and further 5’ and/or 3’ nucleosides.
  • the further 5’ and/or 3’ nucleosides may or may not be fully complementary to the target nucleic acid.
  • Such further 5’ and/or 3’ nucleosides may be referred to as region D’ and D” herein.
  • region D’ or D may be used for the purpose of joining the contiguous nucleotide sequence, such as the gapmer, to a conjugate moiety or another functional group.
  • region D may be used for joining the contiguous nucleotide sequence with a conjugate moiety.
  • a conjugate moiety is can serve as a biocleavable linker. Alternatively it may be used to provide exonucleoase protection or for ease of synthesis or manufacture.
  • Region D’ and D can be attached to the 5’ end of region F or the 3’ end of region F’, respectively to generate designs of the following formulas D’-F-G-F’, F-G-F’-D” or
  • F-G-F’ is the gapmer portion of the oligonucleotide and region D’ or D” constitute a separate part of the oligonucleotide.
  • Region D’ or D may independently comprise or consist of 1 , 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid.
  • the nucleotide adjacent to the F or F’ region is not a sugar-modified nucleotide, such as a DNA or RNA or base modified versions of these.
  • the D’ or D’ region may serve as a nuclease susceptible
  • biocleavable linker see definition of linkers.
  • the additional 5’ and/or 3’ end nucleotides are linked with phosphodiester linkages, and are DNA or RNA.
  • Nucleotide based biocleavable linkers suitable for use as region D’ or D” are disclosed in WO
  • the oligonucleotide of the invention comprises a region D’ and/or D” in addition to the contiguous nucleotide sequence which constitutes the gapmer.
  • the oligonucleotide of the present invention can be represented by the following formulae:
  • F-G-F’ in particular F 1-8 -G 5-i 6 -F’ 2-8
  • D’-F-G-F’ in particular D’ 1-3 -F 1 -8 -G 5-i 6 -F’ 2-8
  • F-G-F’-D in particular F 1-8 -G 5-I 6 -F’2-8-D” 1-3
  • the internucleoside linkage positioned between region D’ and region F is a phosphodiester linkage. In some embodiments the internucleoside linkage positioned between region F’ and region D” is a phosphodiester linkage.
  • conjugate refers to an oligonucleotide which is covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region).
  • Conjugation of the oligonucleotide of the invention to one or more non-nucleotide moieties may improve the pharmacology of the oligonucleotide, e.g. by affecting the activity, cellular distribution, cellular uptake or stability of the oligonucleotide.
  • the conjugate moiety modify or enhance the pharmacokinetic properties of the oligonucleotide by improving cellular distribution, bioavailability, metabolism, excretion, permeability, and/or cellular uptake of the oligonucleotide.
  • the conjugate may target the oligonucleotide to a specific organ, tissue or cell type and thereby enhance the effectiveness of the oligonucleotide in that organ, tissue or cell type.
  • the conjugate may serve to reduce activity of the oligonucleotide in non-target cell types, tissues or organs, e.g. off target activity or activity in non-target cell types, tissues or organs.
  • WO 93/07883 and WO2013/033230 provides suitable conjugate moieties, which are hereby incorporated by reference. Further suitable conjugate moieties are those capable of binding to the asialoglycoprotein receptor (ASGPr).
  • N-acetylgalactosamine conjugate moieties are suitable for binding to the ASGPr, see for example WO 2014/076196, WO 2014/207232 and WO 2014/179620 (hereby incorporated by reference, in particular, Figure 13 of WO2014/076196 or claims 158-164 of
  • Oligonucleotide conjugates and their synthesis has also been reported in comprehensive reviews by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, S.T. Crooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.
  • the non-nucleotide moiety is selected from the group consisting of carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins (e.g. bacterial toxins), vitamins, viral proteins (e.g. capsids) or combinations thereof.
  • a linkage or linker is a connection between two atoms that links one chemical group or segment of interest to another chemical group or segment of interest via one or more covalent bonds.
  • Conjugate moieties can be attached to the oligonucleotide directly or through a linking moiety
  • Linkers serve to covalently connect a third region (region C), e.g. a conjugate moiety to a first region, e.g. an oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A), thereby connecting one of the termini of region A to C.
  • region C e.g. a conjugate moiety to a first region, e.g. an oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A), thereby connecting one of the termini of region A to C.
  • the conjugate or oligonucleotide conjugate of the invention may optionally, comprise a linker region (second region or region B) which is positioned between the oligonucleotide or the contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region) and the conjugate moiety (region C or third region).
  • second region or region B which is positioned between the oligonucleotide or the contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region) and the conjugate moiety (region C or third region).
  • Region B refers to biocleavable linkers comprising or consisting of a physiologically labile bond that is cleavable under conditions normally encountered or analogous to those encountered within a mammalian body.
  • Conditions under which physiologically labile linkers undergo chemical transformation include chemical conditions such as pH, temperature, oxidative or reductive conditions or agents, and salt concentration found in or analogous to those encountered in mammalian cells.
  • Mammalian intracellular conditions also include the presence of enzymatic activity normally present in a mammalian cell such as from proteolytic enzymes or hydrolytic enzymes or nucleases.
  • the biocleavable linker is susceptible to S1 nuclease cleavage.
  • the nuclease susceptible linker comprises between 1 and 10 nucleosides, such as 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleosides, more preferably between 2 and 6 nucleosides and most preferably between 2 and 4 linked nucleosides comprising at least two consecutive phosphodiester linkages, such as at least 3 or 4 or 5 consecutive phosphodiester linkages.
  • the nucleosides are DNA or RNA.
  • Conjugates may also be linked to the oligonucleotide via non-biocleavable linkers, or in some embodiments the conjugate may comprise a non-cleavable linker which is covalently attached to the biocleavable linker (region Y).
  • Linkers that are not necessarily biocleavable but primarily serve to covalently connect a conjugate moiety (region C or third region), to an oligonucleotide (region A or first region), may comprise a chain structure or an oligomer of repeating units such as ethylene glycol, amino acid units or amino alkyl groups
  • the oligonucleotide conjugates of the present invention can be constructed of the following regional elements A-C, A-B-C, A-B-Y-C, A-Y-B-C or A-Y-C.
  • the non-cleavable linker (region Y) is an amino alkyl, such as a C2 - C36 amino alkyl group, including, for example C6 to C12 amino alkyl groups.
  • the linker (region Y) is a C6 amino alkyl group.
  • Conjugate linker groups may be routinely attached to an oligonucleotide via use of an amino modified oligonucleotide, and an activated ester group on the conjugate group. Treatment
  • the invention relates to oligonucleotides capable of reducing the expression of CSNK1 D.
  • the reduction is achieved by hybridizing to a target nucleic acid encoding CSNK1 D or which is involved in the regulation of CSNK1 D.
  • the target nucleic acid may be a part of mammalian CSNK1 D sequence, selected from the group consisting of SEQ ID NO: 1 , 2, 3, 4, 5 and 6 or naturally occurring variants thereof.
  • the oligonucleotide of the invention is an antisense
  • oligonucleotide which targets CSNK1 D pre-mRNA of SEQ ID NO: 1 .
  • the antisense oligonucleotide of the invention is capable of modulating the expression of the target by inhibiting or reducing target expression.
  • a reduction of expression of at least 20% compared to the normal expression level of the target more preferably at least 30%, 40%, 50%, 60%, 70%, 80% 90% or 95% inhibition compared to the normal expression level of the target.
  • oligonucleotides of the invention may be capable of inhibiting expression levels of CSNK1 D mRNA by at least 60% or 70% in vitro using HeLa cells.
  • compounds of the invention may be capable of inhibiting expression levels of CSNK1 D protein by at least 50% in vitro using HeLa cells.
  • the examples provide assays which may be used to measure CSNK1 D RNA or protein inhibition (e.g. example 1 ).
  • the target modulation is triggered by the hybridization between a contiguous nucleotide sequence of the oligonucleotide and the target nucleic acid.
  • the oligonucleotide of the invention comprises mismatches between the oligonucleotide and the target nucleic acid. Despite mismatches hybridization to the target nucleic acid may still be sufficient to show a desired modulation of CSNK1 D expression.
  • Reduced binding affinity resulting from mismatches may advantageously be compensated by increased number of nucleotides in the oligonucleotide and/or an increased number of modified nucleosides capable of increasing the binding affinity to the target, such as 2’sugar modified nucleosides, including LNA, present within the oligonucleotide sequence.
  • the oligonucleotide of the invention comprises a contiguous nucleotide sequence which is complementary to or hybridizes to the target nucleic acid, such as a target sequence as described herein.
  • An aspect of the present invention relates to a antisense oligonucleotide of 10 to 50, such as 10 - 30, nucleotides in length, which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity, such as full complementarity, to a mammalian CSNK1 D target nucleic acid, wherein the antisense oligonucleotide is capable of reducing the expression of the mammalian CSNK1 D target nucleic acid in a cell.
  • An aspect of the present invention relates to an antisense oligonucleotide of 10 to 30 nucleotides in length, which comprises a contiguous nucleotide sequence of 10 to 22 nucleotides in length with at least 90% complementarity, such as full complementarity, to a mammalian CSNK1 D target nucleic acid, wherein the antisense oligonucleotide is capable of reducing the expression of the mammalian CSNK1 D target nucleic acid in a cell.
  • the antisense gapmer oligonucleotide comprises a contiguous sequence which is at least 90% complementary, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, or 100% complementary to the target nucleic acid or the target sequence.
  • the antisense oligonucleotide of the invention or contiguous nucleotide sequence thereof is fully complementary (100% complementary) to a target nucleic acid or target sequence, or in some embodiments may comprise one or two mismatches between the oligonucleotide and the target nucleic acid.
  • Another aspect of the present invention relates to the antisense oligonucleotide, wherein the contiguous nucleotide sequence is at least 90% complementary to a sequence selected from the group consisting of SEQ ID N01 , 2, 3, 4, 5, and 6, or a naturally occurring variant thereof.
  • the oligonucleotide sequence or contiguous nucleotide sequence is at least 90% complementary to a target sequence present in SEQ ID NO: 1 and 6. In some embodiments the contiguous sequence of the antisense oligonucleotide is 100%
  • oligonucleotide sequence or contiguous nucleotide sequence is 100% complementary to a corresponding target sequence present in SEQ ID NO: 1 and SEQ ID NO: 6.
  • Another aspect of the present invention relates to the antisense oligonucleotide, wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to an intron region present in the pre-mRNA of mammalian CSNK1 D target nucleic acid (e.g. SEQ ID NO: 1 ).
  • intron positions on SEQ ID NO: 1 may vary depending on different splicing of CSNK1 D pre-mRNA.
  • any nucleotide sequence in the gene sequence or pre-mRNA that is removed from the pre-mRNA by RNA splicing during maturation of the final RNA product (mature mRNA) are introns irrespectively on their position on SEQ ID NO: 1.
  • Table 1 provides the most common intron regions in SEQ ID NO: 1.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to an intron region present in the pre-mRNA of human CSNK1 D selected from position 427-7935 on SEQ ID NO 1 ; position 8047-18154 on SEQ ID NO 1 , position 18304-20487 on SEQ ID NO 1 , position 20717-21 127 on SEQ ID NO 1 , position 21299-22204 on SEQ ID NO 1 , position 22354-24129 on SEQ ID NO 1 , position 24302-24717 on SEQ ID NO 1 , position 24858- 33669 on SEQ ID NO 1.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to nucleotides position 427-7935 of SEQ ID NO 1 or to position 4979- to 4997 of SEQ ID NO: 1.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to position 8047-18154 of SEQ ID NO: 1 or to position 1 1771 - 1 1790 of SEQ ID NO: 1 or to position 12892-13830 of SEQ ID NO: 1 or to position 12898-13820 of SEQ ID NO: 1 or or to position 12909-13830 of SEQ ID NO: 1.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 7.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 8.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 25.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 26.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 27.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 28.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 29.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 30.
  • the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 31 . In some embodiments the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO: 32.
  • the oligonucleotide or the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to a target region of SEQ ID NO 1 , selected from the group consisting of position 12898-12917, 12946-12965, 13009-13028, 13033-13052, 13057-13076, 13168-13187, 13192-1321 1 , 13216-13235, 13240-13259, 13279-13298, 13303- 13322, 13342-13361 , 13390-13409, 13453-13472, 13501 -13520, 13547-13566, 13571 -13590, 13595-13614, 13651 -13670, 13675-13694, 13714-13733, 13738-13757, 13801 -13820; 12900- 12917, 12948-12965, 1301 1 -13028, 13035-13052, 13059-13076, 13170-13187, 13194
  • the oligonucleotide or the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to a target region of SEQ ID NO 1 , selected from the group consisting of position 12909-12924, 13179-13194, 13203-13218, 13251 -13266, 13290-13305, 13314-13329, 13401 -13416, 13488-13503, 13582-13597, 13725-13740, 13812- 13827; 13178-13197, 13202-13221 , 13250-13269, 13289-13308, 13313-13332, 13400-13419, 13487-13506, 13581 -13600, 13724-13743, 1381 1 -13830; 13179-13196, 13203-13220, 13251 - 13268, 13290-13307, 13314-13331 , 13401 -13418, 13488-13505, 13582-13599, 13725-13742
  • the target sequence is repeated within the target nucleic acid, i.e. at least two identical target nucleotide sequences (target regions) of at least 10 nucleotides in length occur in the target nucleic acid at different positions.
  • a repeated target region is generally between 10 and 50 nucleotides, such as between 1 1 and 30 nucleotides, such as between 12 and 25 nucleotides, such as between 13 and 22 nucleotides, such as between 14 and 20 nucleotides, such as between 15 and 19 nucleotides, such as between 16 and 18 nucleotides.
  • the repeated target region is between 14 and 20 nucleotides.
  • the invention provides antisense oligonucleotides wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to a target region that is repeated at least 2 times across the target nucleic acid of SEQ ID NO: 1 .
  • the effect of this is that several oligonucleotide compounds (with the same sequence) can hybridize to one or more target regions on the same target nucleic acid (at the same time), which may result in multiple cleavage events of the target nucleic acid when the oligonucleotide is administered to a cell or an animal or a human.
  • the oligonucleotide or the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary to a target region that is repeated at least 5 times, such as at least 6, 7, 8, 9, 10, 1 1 , 12, 13, 14 or 15 times, or that is repeated more than 18 times.
  • the target region is repeated between 10 and 25 times within intron 2.
  • the antisense oligonucleotide comprises a contiguous nucleotide sequence that is at least 90% complementary, such as fully complementary, to a target region of 10-22, such as 14-20, nucleotides in length of the target nucleic acid of SEQ ID NO: 1 , wherein the target region is repeated at least 5 or more times across the introns of the target nucleic acid.
  • the antisense oligonucleotide of the invention or the contiguous nucleotide sequence thereof is complementary to at least 10, such as between 10 and 25, repeated target regions in SEQ ID NO: 32.
  • the oligonucleotide of the invention comprises or consists of 10 to 35 nucleotides in length, such as from 10 to 30, such as 1 1 to 22, such as from 12 to 20, such as from 14 to 18 or 14 to 16 contiguous nucleotides in length.
  • the oligonucleotide comprises or consists of 14 to 20 nucleotides in length.
  • the oligonucleotide or contiguous nucleotide sequence thereof comprises or consists of 22 or less nucleotides, such as 20 or less nucleotides, such as less than 18, such as 14, 15, 16 or 17 nucleotides.
  • the contiguous nucleotide sequence comprises or consists of 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides in length.
  • the oligonucleotide comprises or consists of 14 to 20 nucleotides in length.
  • any range given herein includes the range endpoints. Accordingly, if an oligonucleotide is said to include from 10 to 30 nucleotides, both 10 and 30 nucleotides are included. In some embodiments the contiguous nucleotide sequence of the invention is at least 90% identical, such as 100% identical to a sequence selected from the group consisting of SEQ ID NO: 9, 10, 1 1 and 12,.
  • the contiguous nucleotide sequence of the invention is at least 90% identical, such as 100% identical to a sequence selected from the group consisting of SEQ ID NO: 13, 14, 15 and 16.
  • the contiguous nucleotide sequence of the invention is at least 90% identical, such as 100% identical to a sequence selected from the group consisting of SEQ ID NO: 17, 18, 19, and 20.
  • the contiguous nucleotide sequence of the invention is at least 90% identical, such as 100% identical to a sequence selected from the group consisting of SEQ ID NO: 21 , 22, 23 and 24.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 10 to 30 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 9, 10, 1 1 or 12.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 10 to 30 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 13, 14, 15 or 16.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 10 to 30 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 17, 18, 19 or 20.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 10 to 30 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 21 , 22, 23 or 24.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 12 to 20 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 9, 10, 1 1 , and 12.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 12 to 20 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 13, 14, 15 or 16.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 12 to 20 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 17, 18, 19, and 20. In some embodiments the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 12 to 20 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 21 , 22, 23 or 24.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 14 to 20 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 9, 10, 1 1 ir 12,.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 14 to 20 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 13, 14, 15 or 16.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 14 to 20 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 17, 18, 19 or20.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof consists or comprises of 14 to 20 contiguous nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from SEQ ID NO: 21 , 22, 23 or 24.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof comprises a sequence selected from SEQ ID NO 9, 10, 1 1 or 12.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof comprises a sequence selected from SEQ ID NO: 13, 14, 15 or 16.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof comprises a sequence selected from SEQ ID NO: 17, 18, 19 and 20.
  • the antisense oligonucleotide or contiguous nucleotide sequence thereof comprises a sequence selected from SEQ ID NO: 21 , 22, 23 or 24.
  • Oligonucleotide compounds represent specific designs of a motif sequence.
  • Capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and 5-methyl DNA cytosines are presented by“e”, all internucleoside linkages are, preferably, phosphorothioate internucleoside linkages.
  • the contiguous nucleobase sequences can be modified to for example increase nuclease resistance and/or binding affinity to the target nucleic acid. Modifications are described in the definitions and in the“Oligonucleotide design” section. Table 4 lists preferred designs of each motif sequence.
  • oligonucleotide design The pattern in which the modified nucleosides (such as high affinity modified nucleosides) are incorporated into the oligonucleotide sequence is generally termed oligonucleotide design.
  • the oligonucleotides of the invention are designed with modified nucleosides and DNA nucleosides.
  • high affinity modified nucleosides are used.
  • the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 1 1 , at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides.
  • the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides. Suitable modifications are described in the“Definitions” section under“modified nucleoside”,“high affinity modified nucleosides”, “sugar modifications”,“2’ sugar modifications” and Locked nucleic acids (LNA)”.
  • the oligonucleotide comprises one or more sugar modified nucleosides, such as 2’ sugar modified nucleosides.
  • the oligonucleotide of the invention comprise one or more 2’ sugar modified nucleoside independently selected from the group consisting of 2’-0- alkyl-RNA, 2’-0-methyl-RNA, 2’-alkoxy-RNA, 2’-0-methoxyethyl-RNA, 2’-amino-DNA, 2’-fluoro- DNA, arabino nucleic acid (ANA), 2’-fluoro-ANA and LNA nucleosides. It is advantageous if one or more of the modified nucleoside(s) is a locked nucleic acid (LNA).
  • LNA locked nucleic acid
  • the oligonucleotide comprises at least one modified internucleoside linkage. Suitable internucleoside modifications are described in the“Definitions” section under “Modified internucleoside linkage”. It is advantageous if at least 75%, such as all, the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate internucleoside linkages. In some embodiments all the internucleotide linkages in the contiguous sequence of the oligonucleotide are phosphorothioate linkages.
  • the oligonucleotide of the invention comprises at least one LNA nucleoside, such as 1 , 2, 3, 4, 5, 6, 7, or 8 LNA nucleosides, such as from 2 to 6 LNA nucleosides, such as from 3 to 7 LNA nucleosides, 4 to 8 LNA nucleosides or 3, 4, 5, 6, 7 or 8 LNA nucleosides.
  • at least 75% of the modified nucleosides in the oligonucleotide are LNA nucleosides, such as 80%, such as 85%, such as 90% of the modified nucleosides are LNA nucleosides.
  • all the modified nucleosides in the oligonucleotide are LNA nucleosides.
  • the oligonucleotide may comprise both beta-D-oxy-LNA, and one or more of the following LNA nucleosides: thio-LNA, amino-LNA, oxy-LNA, ScET and/or ENA in either the beta-D or alpha-L configurations or combinations thereof.
  • all LNA cytosine units are 5-methyl-cytosine.
  • the nuclease stability of the oligonucleotide or contiguous nucleotide sequence is advantageous for the nuclease stability of the oligonucleotide or contiguous nucleotide sequence to have at least 1 LNA nucleoside at the 5’ end and at least 2 LNA nucleosides at the 3’ end of the nucleotide sequence.
  • the oligonucleotide of the invention is capable of recruiting RNase H.
  • an advantageous structural design is a gapmer design as described in the“Definitions” section under for example“Gapmer”,“LNA Gapmer”,“MOE gapmer” and “Mixed Wing Gapmer”“Alternating Flank Gapmer”.
  • the gapmer design includes gapmers with uniform flanks, mixed wing flanks, alternating flanks, and gapbreaker designs.
  • the oligonucleotide of the invention is a gapmer with an F-G-F’ design.
  • the gapmer is an LNA gapmer with uniform flanks.
  • the LNA gapmer is selected from the following uniform flank designs
  • the F-G-F’ design is selected from 2-16-2, 3-13-2, 3-12- 3, 4-9-3, 3-9-4, 2-8-4 or 3-7-4.
  • the antisense oligonucleotide is selected from the group of oligonucleotide compounds with CMP ID NO 9_1 , 10_1 , 1 1 _ 1 or12 1 ,.
  • the antisense oligonucleotide is selected from the group of oligonucleotide compounds with CMP ID NO 1 , 13_1 , 14 1 , 15 _ 1 , 16_1
  • the antisense oligonucleotide is selected from the group of oligonucleotide compounds with CMP ID NO: 17 1 , 18_1 , 19 1 or20_1 .
  • the antisense oligonucleotide is selected from the group of oligonucleotide compounds with CMP ID NO: 20_1 , 21 1 , 22 1 , 23_1 or 24 1 .
  • the invention provides methods for manufacturing the oligonucleotides of the invention comprising reacting nucleotide units and thereby forming covalently linked contiguous nucleotide units comprised in the oligonucleotide.
  • the method uses phophoramidite chemistry (see for example Caruthers et al, 1987, Methods in Enzymology vol. 154, pages 287- SI 3).
  • the method further comprises reacting the contiguous nucleotide sequence with a conjugating moiety (ligand).
  • composition of the invention comprising mixing the oligonucleotide or conjugated oligonucleotide of the invention with a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
  • the invention provides a pharmaceutically acceptable salt of the antisense oligonucleotide or a conjugate thereof.
  • the pharmaceutically acceptable salt is a sodium or a potassium salt.
  • the invention provides pharmaceutical compositions comprising any of the aforementioned oligonucleotides and/or oligonucleotide conjugates or salts thereof and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
  • a pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS) and pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.
  • the pharmaceutically acceptable diluent is sterile phosphate buffered saline.
  • the oligonucleotide is used in the pharmaceutically acceptable diluent at a concentration of 50 - 300mM solution.
  • Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see, e.g., Langer (Science 249:1527-1533, 1990).
  • WO 2007/031091 provides further suitable and preferred examples of pharmaceutically acceptable diluents, carriers and adjuvants (hereby incorporated by reference).
  • Suitable dosages, formulations, administration routes, compositions, dosage forms, combinations with other therapeutic agents, pro-drug formulations are also provided in W02007/031091.
  • Oligonucleotides or oligonucleotide conjugates of the invention may be mixed with
  • compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.
  • compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered.
  • the resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the preparations typically will be between 3 and 1 1 , more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5.
  • the resulting compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules.
  • the composition in solid form can also be packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment.
  • the oligonucleotide or oligonucleotide conjugate of the invention is a prodrug.
  • the conjugate moiety is cleaved of the oligonucleotide once the prodrug is delivered to the site of action, e.g. the target cell.
  • oligonucleotides of the invention may be utilized as research reagents for, for example, diagnostics, therapeutics and prophylaxis.
  • oligonucleotides may be used to specifically modulate the synthesis of CSNK1 D protein in cells (e.g. in vitro cell cultures) and experimental animals thereby facilitating functional analysis of the target or an appraisal of its usefulness as a target for therapeutic intervention.
  • the target modulation is achieved by degrading or inhibiting the pre- mRNA or mRNA producing the protein, thereby prevent protein formation or by degrading or inhibiting a modulator of the gene or mRNA producing the protein.
  • Further advantages may be achieved by targeting pre-mRNA thereby preventing formation of the mature mRNA.
  • the target nucleic acid may be a cDNA or a synthetic nucleic acid derived from DNA or RNA.
  • the present invention provides an in vivo or in vitro method for modulating CSNK1 D expression in a target cell which is expressing CSNK1 D, said method comprising administering an oligonucleotide of the invention in an effective amount to said cell.
  • the target cell is a mammalian cell in particular a human cell.
  • the target cell may be an in vitro cell culture or an in vivo cell forming part of a tissue in a mammal.
  • the target cell is present in oral mucosa, cerebral cortex, thyroid glands, caudate, placenta adrenal gland, appendix, endometrium, tonsil, epididymis, lung, nasopharynx, bronchus, urinary bladder, testis, gallbladder, pancreas, salivary gland, hippocampus, esophagus, stomach, duodenum, kidney, colon rectum and skin.
  • CSNK1 D is also overexpressed in cancer cells, such as breast cancer or liver cancer cells.
  • the target cell is a cancer cell or a precancerous cell.
  • the target cell is a pre-metastatic or a metastatic cancer cell.
  • oligonucleotides, conjugates or compositions of the invention may be used to detect and quantitate CSNK1 D expression in cell and tissues by northern blotting, in-situ hybridization or similar techniques.
  • the oligonucleotides, conjugates or compositions of the invention can be used in an animal or a human, suspected of having a disease or disorder, which can be treated by modulating the expression of CSNK1 D.
  • the invention provides methods for treating or preventing a disease, comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide, an oligonucleotide conjugate or a pharmaceutical composition of the invention to a subject suffering from or susceptible to the disease.
  • the invention also relates to an oligonucleotide, a composition or a conjugate as defined herein for use as a medicament.
  • oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition according to the invention is typically administered in an effective amount.
  • the invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament for the treatment of a disorder as referred to herein, or for a method of the treatment of as a disorder as referred to herein.
  • the disease or disorder is associated with expression of CSNK1 D.
  • the methods of the invention are preferably employed for treatment or prophylaxis against diseases caused by abnormal levels and/or activity of CSNK1 D.
  • the invention further relates to use of an oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of abnormal levels and/or activity of CSNK1 D.
  • the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the treatment of cancer, in particular cancers where CSNK1 D is over expressed in the cancer cell.
  • the Cancers can be selected from the group consisting of breast cancer, liver cancer, lung cancer, cervical cancer, melanoma, glioblastoma, medulloblastoma, pancreatic cancer, prostate cancer, renal cancer, bladder cancer, endometrial cancer, stomach cancer, colon cancer, testis cancer, urothelial cancer and metastatic cancer.
  • breast cancer or liver cancer or metastatic cancer is suitable for treatment with the oligonucleotides, oligonucleotide conjugates and pharmaceutical compositions of the present invention.
  • Metastatic cancer where CSNK1 D positive metastases are found in the brain, lymph nodes, lung, or bone are diseases which may benefit from treatment with oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions of the present invention.
  • composition of the invention is for use in a combination treatment with another therapeutic agent.
  • the therapeutic agent can for example be the standard of care for the cancers described above.
  • oligonucleotides or pharmaceutical compositions of the present invention may be administered enteral (such as, orally or through the gastrointestinal tract) or parenteral (such as, intravenous, subcutaneous, intra-muscular, intracerebral, intracerebroventricular or intrathecal).
  • parenteral such as, intravenous, subcutaneous, intra-muscular, intracerebral, intracerebroventricular or intrathecal.
  • the antisense oligonucleotide, a conjugate, a pharmaceutical salt or pharmaceutical compositions of the present invention are administered by a parenteral route including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion.
  • the active oligonucleotide or oligonucleotide conjugate is administered intravenously.
  • the active antisense oligonucleotide or antisense oligonucleotide conjugate is administered subcutaneously.
  • the antisense gapmer oligonucleotide, oligonucleotide conjugate, the pharmaceutical salt of the invention or pharmaceutical composition of the invention is administered at a dose of 0.1 - 15 mg/kg, such as from 0.2 - 10 mg/kg, such as from 0.25 - 5 mg/kg.
  • the administration can be once a week, every 2 nd week, every third week or even once a month.
  • the invention also provides for the use of the antisense oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for subcutaneous administration.
  • the invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for intravenous administration.
  • An antisense oligonucleotide of 10 to 50 nucleotides in length which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity, such as fully complementary, to a mammalian CSNK1 D target nucleic acid, wherein the antisense oligonucleotide is capable of reducing the expression of the mammalian CSNK1 D target nucleic acid, in a cell.
  • the antisense oligonucleotide according to embodiment 1 wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary to a sequence selected from the group consisting of SEQ ID NO: 1 , 2, 3, 4, 5 and 6, or a naturally occurring variant thereof.
  • antisense oligonucleotide according to any one of embodiments 1 to 5, wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to position 427-7935 of SEQ ID NO: 1 or to position 4979- to 4997 of SEQ ID NO: 1 .
  • oligonucleotide is capable of hybridizing to a target nucleic acid selected from the group consisting of SEQ ID NO: 1 , 2, 3, 4, 5 and 6 with a AG° below -10 kcal.
  • the antisense oligonucleotide of any one of embodiments 1 to 16 wherein the contiguous nucleotide sequence comprises or consists of from 14 to 20 nucleotides.
  • oligonucleotide or contiguous nucleotide sequence is single stranded.
  • oligonucleotide is neither siRNA nor self-complementary.
  • antisense oligonucleotide of any one of embodiments 1 to 6 or 8 to 21 (excluding dependency on embodiments 7, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from SEQ ID NO: 9, 10, 1 1 or12,.
  • oligonucleotide comprises at least one modified internucleoside linkage.
  • oligonucleotide is capable of recruiting RNase H.
  • nucleosides of which 1 -4 are 2’ sugar modified and defines the 5’ and 3’ end of the F and F’ region, and G is a region between 6 and 16 nucleosides which are capable of recruiting
  • antisense oligonucleotide of any one of embodiments 42-45 wherein the LNA nucleoside is selected from beta- D-oxy- LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L- amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, (S)cET, (R)cET beta-D-ENA and alpha-L-ENA.
  • nucleoside is oxy-LNA.
  • antisense oligonucleotide of any one of embodiments 42-45 wherein the LNA nucleoside is amino-LNA.
  • antisense oligonucleotide or contiguous nucleotide sequence thereof is selected from the group consisting of
  • GAtgtgactgatggtgtaCT Compound ID 17 1
  • GATgtgactgatggtGTA Compound ID 18_1 );
  • ATGTgactgatggTGT Compound ID 19 1
  • GTgactgatgGTGT Compound ID 20_1
  • capital letters represent LNA nucleosides, such as beta-D-oxy LNA
  • lower case letters represent DNA nucleosides
  • all LNA C are 5-methyl cytosine
  • at least one, preferably all internucleoside linkages are phosphorothioate internucleoside linkages.
  • antisense oligonucleotide according to any one of embodiments 1 - 5 or 7, 8, 10 to 21 (excluding dependency on embodiments 6 and 9), 25 to 57 (excluding dependency on embodiments 6, 9, 22, 23 and 24), wherein the antisense oligonucleotide or contiguous nucleotide sequence thereof is selected from the group consisting ACTgagtgatgtGACT
  • oligonucleotide of embodiment 60 wherein the oligonucleotide is selected from CMP ID NO: 21_1 ; 22_1 ; 23_1 ; or 24_1
  • oligonucleotide of embodiment 62 wherein the oligonucleotide is selected from CMP ID NO: 9 1 ; 10_1 ; 1 1_1 ; or 12_1 .
  • the antisense oligonucleotide according to any one of embodiments 1 to 5, 7 or 12 to 21 (excluding dependency on embodiment 6 and 8 to 1 1 ), or 24 or 26 to 57 (excluding dependency on embodiments on embodiment 4, 8 to 1 1 , 22), wherein the antisense oligonucleotide or contiguous nucleotide sequence thereof is selected from the group consisting of GCtgtgaactaagtaaTGT (Compound ID 13_1 ); TGTGaactaagtaaATGT (Compound ID 14 1 ); GCTGtgaactaaGTAA (Compound ID 15_1 ); GCTGtgaactAAGT (Compound ID 16_1 ), wherein capital letters represent LNA nucleosides, such as beta-D-oxy LNA, lower case letters represent DNA nucleosides, optionally all LNA C are 5-methyl cytosine, and at least one, preferably all internucleoside linkages are phosphorothioate
  • a conjugate comprising the antisense oligonucleotide according to any one of embodiments 1 to 65, and at least one conjugate moiety covalently attached to said antisense oligonucleotide.
  • the antisense oligonucleotide conjugate of embodiment 66 wherein the conjugate moiety is selected from carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins, vitamins, viral proteins or
  • oligonucleotide has the formula D’-F-G-F’ or F-G-F’-D”, wherein F, F’ and G are as defined in embodiments 40 to 57 and D’ or D” comprises 1 , 2 or 3 DNA nucleosides with phosphorothioate internucleoside linkages.
  • a pharmaceutical composition comprising the antisense oligonucleotide of any one of embodiments 1 to 65 or the conjugate according to any of embodiments 66 to 72, or the pharmaceutically acceptable salt of embodiment 73 and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
  • a method for manufacturing the composition of embodiment 74 comprising mixing the oligonucleotide with a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
  • An in vivo or in vitro method for reducing CSNK1 D expression in a target cell which is expressing the mammalian CSNK1 D comprising administering the antisense oligonucleotide of any one of embodiments 1 to 65 or the conjugate according to any of embodiments 66 to 72 or the pharmaceutical salt of embodiment 73 or the pharmaceutical composition of embodiment 74 in an effective amount to said cell.
  • a method for treating, alleviating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of the antisense oligonucleotide of any one of embodiments 1 to 65 or the conjugate according to any of embodiments 66 to 72 or the pharmaceutical salt of embodiment 73 or the pharmaceutical composition of embodiment 74 to a subject suffering from or susceptible to the disease.
  • composition of embodiment 74 for use as a medicament for treatment alleviation or prevention of a disease in a subject.
  • oligonucleotide of antisense oligonucleotide of any one of embodiment 1 to 65 or the conjugate according to any of embodiments 66 to 72 for the preparation of a medicament for treatment or prevention of a disease in a subject.
  • the antisense oligonucleotide or the use of embodiment 85 where the cancer is selected from the group consisting of breast cancer, liver cancer, lung cancer, cervical cancer, melanoma, glioblastoma, medulloblastoma, pancreatic cancer, prostate cancer, renal cancer, bladder cancer, endometrial cancer, stomach cancer, colon cancer, testis cancer, urothelial cancer, or a cancer that metastasizes to the brain, lymph nodes, lung, or bone.
  • Table 4 list of oligonucleotide motif sequences (indicated by SEQ ID NO), designs of these, as well as specific oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.
  • Motif sequences represent the contiguous sequence of nucleobases present in the oligonucleotide.
  • Oligonucleotide compounds represent specific designs of a motif sequence.
  • Capital letters represent beta-D-oxy LNA nucleosides
  • lowercase letters represent DNA nucleosides
  • all LNA C are 5-methyl cytosine
  • 5-methyl DNA cytosines are presented by“e”
  • all internucleoside linkages are phosphorothioate internucleoside linkages.
  • Oligonucleotide synthesis is generally known in the art. Below is a protocol which may be applied. The oligonucleotides of the present invention may have been produced by slightly varying methods in terms of apparatus, support and concentrations used.
  • Oligonucleotides are synthesized on uridine universal supports using the phosphoramidite approach on an Oligomaker 48 at 1 pmol scale. At the end of the synthesis, the oligonucleotides are cleaved from the solid support using aqueous ammonia for 5-16hours at 60 ° C. The oligonucleotides are purified by reverse phase HPLC (RP-HPLC) or by solid phase extractions and characterized by UPLC, and the molecular mass is further confirmed by ESI-MS.
  • RP-HPLC reverse phase HPLC
  • UPLC UPLC
  • a C6 linker for attaching a conjugate group or a conjugate group as such.
  • Thiolation for introduction of phosphorthioate linkages is carried out by using xanthane hydride (0.01 M in acetonitrile/pyridine 9:1 ).
  • Phosphordiester linkages can be introduced using 0.02 M iodine in THF/Pyridine/water 7:2:1.
  • the rest of the reagents are the ones typically used for oligonucleotide synthesis.
  • phorphoramidite can be used in the last cycle of the solid phase synthesis and after
  • the conjugates are introduced via activation of the functional group using standard synthesis methods.
  • the crude compounds are purified by preparative RP-HPLC on a Phenomenex Jupiter C18 10m 150x10 mm column. 0.1 M ammonium acetate pH 8 and acetonitrile is used as buffers at a flow rate of 5 mL/min. The collected fractions are lyophilized to give the purified compound typically as a white solid.
  • Oligonucleotide and RNA target (phosphate linked, PO) duplexes are diluted to 3 mM in 500 ml RNase-free water and mixed with 500 ml 2x T m -buffer (200mM NaCI, 0.2mM EDTA, 20mM Naphosphate, pH 7.0). The solution is heated to 95 5 C for 3 min and then allowed to anneal in room temperature for 30 min.
  • the duplex melting temperatures (T m ) is measured on a Lambda 40 UV/VIS Spectrophotometer equipped with a Peltier temperature programmer PTP6 using PE Templab software (Perkin Elmer). The temperature is ramped up from 20 5 C to 95 5 C and then down to 25 5 C, recording absorption at 260 nm. First derivative and the local maximums of both the melting and annealing are used to assess the duplex T m .
  • Oligonucleotides targeting one region as well as oligonucleotides targeting at least three independent regions on CSNK1 D were tested in an in vitro experiment in HeLa cells. EC50 (potency) and max kd (efficacy) was assessed for the oligonucleotides.
  • the HeLa cell line was purchased from European Collection of Authenticated Cell Cultures (ECACC) and maintained as recommended by the supplier in a humidified incubator at 37°C with 5% C0 2 .
  • ECACC European Collection of Authenticated Cell Cultures
  • 2,500 cells/well were seeded in a 96 multi well plate in Eagle's Minimum Essential Medium (Sigma, M4655) with 10% fetal bovine serum (FBS) as
  • oligonucleotides were incubated for 24 hours before addition of oligonucleotides.
  • the oligonucleotides were dissolved in PBS and added to the cells at final concentrations of oligonucleotides was of 0.01 , 0.031 , 0.1 , 0.31 , 1 , 3.21 , 10, and 32.1 mM, the final culture volume was 100 mI/well.
  • the cells were harvested 3 days after addition of oligonucleotide compounds and total RNA was extracted using the PureLink Pro 96 RNA Purification kit (Thermo Fisher Scientific), according to the manufacturer’s instructions..
  • Target transcript levels were quantified using FAM labeled TaqMan assays from Thermo Fisher Scientific in a multiplex reaction with a VIC labelled GAPDH control probe in a technical duplex and biological triplex set up.
  • GAPDH (4326317E VIC®/MGB probe). EC50 and efficacy of the oligonucleotides are shown in Table 5 as % of control sample.

Abstract

La présente invention concerne des oligonucléotides antisens qui sont aptes à réduire l'expression de CSNK1D dans une cellule cible. Les oligonucléotides s'hybrident au pré-ARNm de CSNK1D. La présente invention concerne en outre des conjugués de l'oligonucléotide et des compositions pharmaceutiques et des procédés pour le traitement ou le soulagement de cancers, tels que le cancer du sein, le cancer du foie, le cancer du poumon, le cancer du col de l'utérus, le mélanome, le glioblastome, le médulloblastome, le cancer du pancréas, le cancer de la prostate, le cancer du rein, le cancer de la vessie, le cancer de l'endomètre, le cancer de l'estomac, le cancer du côlon, le cancer des testicules, le cancer urothélial, ou un cancer qui se métastase au cerveau, aux ganglions lymphatiques, aux poumons ou aux os.
PCT/EP2019/051684 2018-01-26 2019-01-24 Oligonucléotides pour la modulation de l'expression de csnk1d WO2019145386A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18153624 2018-01-26
EP18153624.4 2018-01-26

Publications (1)

Publication Number Publication Date
WO2019145386A1 true WO2019145386A1 (fr) 2019-08-01

Family

ID=65237021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/051684 WO2019145386A1 (fr) 2018-01-26 2019-01-24 Oligonucléotides pour la modulation de l'expression de csnk1d

Country Status (1)

Country Link
WO (1) WO2019145386A1 (fr)

Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007883A1 (fr) 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Oligonucleotides derives presentant diverses qualites dont une meilleure facilite d'absorption
WO1998039352A1 (fr) 1997-03-07 1998-09-11 Takeshi Imanishi Nouveaux analogues de bicyclonucleoside et d'oligonucleotide
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO2000047599A1 (fr) 1999-02-12 2000-08-17 Sankyo Company, Limited Nouveaux analogues de nucleosides et d'oligonucleotides
WO2000066604A2 (fr) 1999-05-04 2000-11-09 Exiqon A/S Analogues de l-ribo-lna
WO2001023613A1 (fr) 1999-09-30 2001-04-05 Isis Pharmaceuticals, Inc. Rnase h humaine et compositions nucleotidiques correspondantes
WO2004046160A2 (fr) 2002-11-18 2004-06-03 Santaris Pharma A/S Conception antisens
WO2005103240A1 (fr) 2004-04-24 2005-11-03 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour maladies associees a la caseine kinase1, delta, isoforme1 (csnk1d iso 1)
WO2005105987A1 (fr) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics et therapeutique de maladies associees a la caseine kinase 1, delta, isoforme 2 (csnk1d iso 2)
CN1904900A (zh) * 2005-07-28 2007-01-31 中国科学院生物物理研究所 人类的内源性siRNA序列及其应用和筛选方法
WO2007031091A2 (fr) 2005-09-15 2007-03-22 Santaris Pharma A/S Composes antagonistes d'arn de modulation de l'expression de p21 ras
WO2007090071A2 (fr) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. Analogues d'acides nucleiques bicycliques modifies en position 6
WO2007134181A2 (fr) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques modifiés en 5'
WO2007146511A2 (fr) 2006-05-05 2007-12-21 Isis Pharmaceuticals, Inc. Composés et procédés de modulation de l'expression génique
WO2008049085A1 (fr) 2006-10-18 2008-04-24 Isis Pharmaceuticals, Inc. Composés antisens
WO2008113832A2 (fr) 2007-03-22 2008-09-25 Santaris Pharma A/S Composés arn antagonistes courts pour la modulation de l'arnm cible
WO2008150729A2 (fr) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
WO2008154401A2 (fr) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique bicyclique carbocylique
WO2009006478A2 (fr) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques disubstitués en position 6
WO2009067647A1 (fr) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
WO2009144719A2 (fr) * 2008-05-27 2009-12-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procédé de destruction de cellules et son utilisation dans la prévention et le traitement du cancer
WO2010036698A1 (fr) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Nucléosides alpha-l-bicycliques substitués
WO2010077578A1 (fr) 2008-12-09 2010-07-08 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique bicyclique bis-modifié
WO2011017521A2 (fr) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques cyclohexoses bicycliques
WO2011156202A1 (fr) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. 2'‑amino- et 2'‑thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers
WO2012109395A1 (fr) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations
WO2013022984A1 (fr) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Composés antisens sélectifs et utilisations de ceux-ci
WO2013033230A1 (fr) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Complexes oligomère-conjugué et leur utilisation
WO2013036868A1 (fr) 2011-09-07 2013-03-14 Marina Biotech Inc. Synthèse et utilisations de composés acides nucléiques comportant des monomères restreints de point de vue conformationnel
WO2013120003A1 (fr) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation d'arn par ciblage de répétition
WO2013154798A1 (fr) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Analogues tricycliques d'acide nucléique
WO2014076195A1 (fr) 2012-11-15 2014-05-22 Santaris Pharma A/S Conjugués d'oligonucléotides
WO2014082993A2 (fr) * 2012-11-30 2014-06-05 Galapagos Nv Cibles moléculaires et composés, et procédés d'identification de ceux-ci, utiles dans la régulation à la baisse de la réponse th2
WO2014179620A1 (fr) 2013-05-01 2014-11-06 Isis Pharmaceuticals, Inc. Composés antisens conjugués et leur utilisation
WO2014207232A1 (fr) 2013-06-27 2014-12-31 Santaris Pharma A/S Oligomères antisens et conjugués ciblant pcsk9
WO2015058056A1 (fr) 2013-10-18 2015-04-23 The General Hospital Corporation N-méthyl-pyrazoloanthrone pour le traitement du cancer
WO2015113922A1 (fr) 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Composé poly-oligomérique à conjugués bioclivables
WO2016127002A1 (fr) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Oligonucléotides lna à flancs alternés
WO2017066055A1 (fr) 2015-10-13 2017-04-20 The Scripps Research Institute Ciblage thérapeutique de la caséine kinase 1δ dans le cancer du sein

Patent Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007883A1 (fr) 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Oligonucleotides derives presentant diverses qualites dont une meilleure facilite d'absorption
WO1998039352A1 (fr) 1997-03-07 1998-09-11 Takeshi Imanishi Nouveaux analogues de bicyclonucleoside et d'oligonucleotide
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO2000047599A1 (fr) 1999-02-12 2000-08-17 Sankyo Company, Limited Nouveaux analogues de nucleosides et d'oligonucleotides
WO2000066604A2 (fr) 1999-05-04 2000-11-09 Exiqon A/S Analogues de l-ribo-lna
WO2001023613A1 (fr) 1999-09-30 2001-04-05 Isis Pharmaceuticals, Inc. Rnase h humaine et compositions nucleotidiques correspondantes
WO2004046160A2 (fr) 2002-11-18 2004-06-03 Santaris Pharma A/S Conception antisens
WO2005103240A1 (fr) 2004-04-24 2005-11-03 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour maladies associees a la caseine kinase1, delta, isoforme1 (csnk1d iso 1)
WO2005105987A1 (fr) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics et therapeutique de maladies associees a la caseine kinase 1, delta, isoforme 2 (csnk1d iso 2)
CN1904900A (zh) * 2005-07-28 2007-01-31 中国科学院生物物理研究所 人类的内源性siRNA序列及其应用和筛选方法
WO2007031091A2 (fr) 2005-09-15 2007-03-22 Santaris Pharma A/S Composes antagonistes d'arn de modulation de l'expression de p21 ras
WO2007090071A2 (fr) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. Analogues d'acides nucleiques bicycliques modifies en position 6
WO2007146511A2 (fr) 2006-05-05 2007-12-21 Isis Pharmaceuticals, Inc. Composés et procédés de modulation de l'expression génique
WO2007134181A2 (fr) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques modifiés en 5'
WO2008049085A1 (fr) 2006-10-18 2008-04-24 Isis Pharmaceuticals, Inc. Composés antisens
WO2008113832A2 (fr) 2007-03-22 2008-09-25 Santaris Pharma A/S Composés arn antagonistes courts pour la modulation de l'arnm cible
WO2008150729A2 (fr) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
WO2008154401A2 (fr) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique bicyclique carbocylique
WO2009006478A2 (fr) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques disubstitués en position 6
WO2009067647A1 (fr) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
WO2009144719A2 (fr) * 2008-05-27 2009-12-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procédé de destruction de cellules et son utilisation dans la prévention et le traitement du cancer
WO2010036698A1 (fr) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Nucléosides alpha-l-bicycliques substitués
WO2010077578A1 (fr) 2008-12-09 2010-07-08 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique bicyclique bis-modifié
WO2011017521A2 (fr) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques cyclohexoses bicycliques
WO2011156202A1 (fr) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. 2'‑amino- et 2'‑thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers
WO2012109395A1 (fr) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations
EP2742135A1 (fr) 2011-08-11 2014-06-18 Isis Pharmaceuticals, Inc. Composés oligomères à brèche modifiés par liaison et leurs utilisations
WO2013022984A1 (fr) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Composés antisens sélectifs et utilisations de ceux-ci
WO2013033230A1 (fr) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Complexes oligomère-conjugué et leur utilisation
WO2013036868A1 (fr) 2011-09-07 2013-03-14 Marina Biotech Inc. Synthèse et utilisations de composés acides nucléiques comportant des monomères restreints de point de vue conformationnel
WO2013120003A1 (fr) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation d'arn par ciblage de répétition
WO2013154798A1 (fr) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Analogues tricycliques d'acide nucléique
WO2014076195A1 (fr) 2012-11-15 2014-05-22 Santaris Pharma A/S Conjugués d'oligonucléotides
WO2014076196A1 (fr) 2012-11-15 2014-05-22 Santaris Pharma A/S Composés conjugués antisens anti-apob
WO2014082993A2 (fr) * 2012-11-30 2014-06-05 Galapagos Nv Cibles moléculaires et composés, et procédés d'identification de ceux-ci, utiles dans la régulation à la baisse de la réponse th2
WO2014179620A1 (fr) 2013-05-01 2014-11-06 Isis Pharmaceuticals, Inc. Composés antisens conjugués et leur utilisation
WO2014207232A1 (fr) 2013-06-27 2014-12-31 Santaris Pharma A/S Oligomères antisens et conjugués ciblant pcsk9
WO2015058056A1 (fr) 2013-10-18 2015-04-23 The General Hospital Corporation N-méthyl-pyrazoloanthrone pour le traitement du cancer
WO2015113922A1 (fr) 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Composé poly-oligomérique à conjugués bioclivables
WO2016127002A1 (fr) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Oligonucléotides lna à flancs alternés
WO2017066055A1 (fr) 2015-10-13 2017-04-20 The Scripps Research Institute Ciblage thérapeutique de la caséine kinase 1δ dans le cancer du sein

Non-Patent Citations (45)

* Cited by examiner, † Cited by third party
Title
A.G. GROZAV ET AL.: "Casein kinase I [delta]/[epsilon] phosphorylates Topoisomerase II[alpha] at Serine-1106 and modulates DNA cleavage activity", NUCLEIC ACIDS RESEARCH, vol. 37, no. 2, 28 November 2008 (2008-11-28), pages 382 - 392, XP055575881, ISSN: 0305-1048, DOI: 10.1093/nar/gkn934 *
BAGGS J.E. ET AL.: "Network features of the mammalian circadian clock", PLOS BIOLOGY, vol. 7, no. 3, E1000052, 1 March 2009 (2009-03-01), pages 563 - 575, XP055575871 *
BAGGS J.E. ET AL.: "supplemental data", 1 March 2009 (2009-03-01), XP055575868, Retrieved from the Internet <URL:https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1000052#s4> [retrieved on 20190329] *
BERGSTROM, CURRENT PROTOCOLS IN NUCLEIC ACID CHEMISTRY, 2009, pages 1.4.1
CARUTHERS ET AL., METHODS IN ENZYMOLOGY, vol. 154, 1987, pages 287 - 313
DELEAVEY; DAMHA, CHEMISTRY AND BIOLOGY, vol. 19, 2012, pages 937
EVANTHIA PANGOU ET AL.: "HIF-2[alpha] phosphorylation by CK1[delta] promotes erythropoietin secretion in liver cancer cells under hypoxia", JOURNAL OF CELL SCIENCE, vol. 129, no. 22, 29 September 2016 (2016-09-29), pages 4213 - 4226, XP055575804, ISSN: 0021-9533, DOI: 10.1242/jcs.191395 *
FLUITER ET AL., MOL. BIOSYST., vol. 10, 2009, pages 1039
FREIER; ALTMANN, NUCL. ACID RES., vol. 25, 1997, pages 4429 - 4443
GREER, MBOC, vol. 25, 2014
HANSEN ET AL., CHEM. COMM., 1965, pages 36 - 38
HIRAO ET AL., ACCOUNTS OF CHEMICAL RESEARCH, vol. 45, 2012, pages 2055
HIROTA ET AL.: "supplemental data", 1 December 2010 (2010-12-01), XP055575811, Retrieved from the Internet <URL:https://journals.plos.org/plosbiology/article/file?type=supplementary&id=info:doi/10.1371/journal.pbio.1000559.s011> [retrieved on 20190329] *
HOLDGATE ET AL., DRUG DISCOV TODAY, 2005
LAURA H. ROSENBERG ET AL.: "supplemental data", SCIENCE TRANSLATIONAL MEDICINE, 16 December 2015 (2015-12-16), United States, pages 318ra202 - 318ra202, XP055575807, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809734/> DOI: 10.1126/scitranslmed.aac8773 *
LAURA H. ROSENBERG ET AL.: "Therapeutic targeting of casein kinase 1[delta] in breast cancer", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 318, 16 December 2015 (2015-12-16), US, pages 318ra202 - 318ra202, XP055575851, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aac8773 *
M. QUINTAVALLE ET AL.: "The isoform of Protein Kinase CKI is responsible for Hepatitis C Virus NS5A hyperphosphorylation", JOURNAL OF VIROLOGY, vol. 80, no. 22, 15 November 2006 (2006-11-15), US, pages 11305 - 11312, XP055575876, ISSN: 0022-538X, DOI: 10.1128/JVI.01465-06 *
MANGOS ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 654 - 661
MANOHARAN, ANTISENSE AND NUCLEIC ACID DRUG DEVELOPMENT, vol. 12, 2002, pages 103
MANOHARAN: "Antisense Drug Technology, Principles, Strategies, and Applications", 2001, MARCEL DEKKER, INC.
MCTIGUE ET AL., BIOCHEMISTRY, vol. 43, 2004, pages 5388 - 5405
MERGNY; LACROIX, OLIGONUCLEOTIDES, vol. 13, 2003, pages 515 - 537
MITSUOKA ET AL., NUCLEIC ACIDS RESEARCH, vol. 37, no. 4, 2009, pages 1225 - 1238
MORITA ET AL., BIOORGANIC & MED.CHEM. LETT., vol. 12, pages 73 - 76
PANGOU ET AL., JOURNAL OF CELL SCIENCE, vol. 129, 2016, pages 4213 - 4226
REMINGTON: "Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
ROSENBERG ET AL., SCI TRANLS MED., vol. 7, no. 318, 16 December 2015 (2015-12-16)
RUKOV ET AL., NUCL. ACIDS RES., vol. 43, 2015, pages 8476 - 8487
SANTALUCIA, PROC NATL ACAD SCI USA., vol. 95, 1998, pages 1460 - 1465
SCIENCE, vol. 249, 1990, pages 1527 - 1533
SETH ET AL., J. ORG. CHEM, 2010
SETH ET AL., J. ORG. CHEM., vol. 75, no. 5, 2010, pages 1569 - 81
SETH, J. ORG. CHEM., vol. 75, no. 5, 2010, pages 1569 - 81
SUGIMOTO ET AL., BIOCHEMISTRY, vol. 34, 1995, pages 11211 - 11216
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1999, WILEY
TOMOYUKI YAMANAKA ET AL.: "Large-scale RNA interference screening in mammalian cells identifies novel regulators of mutant Huntingtin aggregation", PLOS ONE, vol. 9, no. 4, 4 April 2014 (2014-04-04), pages e93891, XP055575856, DOI: 10.1371/journal.pone.0093891 *
TSUYOSHI HIROTA ET AL.: "High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKI[alpha] as a clock regulatory Kinase", PLOS BIOLOGY, vol. 8, no. 12, 14 December 2010 (2010-12-14), pages e1000559, XP055575862, DOI: 10.1371/journal.pbio.1000559 *
UHLMANN, CURR. OPINION IN DRUG DEVELOPMENT, vol. 3, no. 2, 2000, pages 293 - 213
VESTER ET AL., BIOORG. MED. CHEM. LETT., vol. 18, 2008, pages 2296 - 2300
VICKERS, PLOS ONE, vol. 9, no. 10, October 2014 (2014-10-01)
YAMANAKA ET AL.: "supplemental data", 4 April 2014 (2014-04-04), XP055575859, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093891#s5> [retrieved on 20190329] *
YOSHIMI ENDO GREER ET AL.: "Casein kinase 1[delta] functions at the centrosome and Golgi to promote ciliogenesis", MOLECULAR BIOLOGY OF THE CELL, vol. 25, no. 10, 15 May 2014 (2014-05-15), US, pages 1629 - 1640, XP055575878, ISSN: 1059-1524, DOI: 10.1091/mbc.e13-10-0598 *
YOSHIMI ENDO GREER ET AL.: "Lack of Casein Kinase 1 delta promotes genomic instability - the accumulation of DNA damage and down-regulation of Checkpoint Kinase 1", PLOS ONE, vol. 12, no. 1, 26 January 2017 (2017-01-26), pages e0170903, XP055575802, DOI: 10.1371/journal.pone.0170903 *
YOSHIMI ENDO GREER ET AL.: "supplemental data", 19 March 2014 (2014-03-19), XP055575879, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019494/> [retrieved on 20190329] *
YOSHIMI ENDO GREER ET AL.: "supplemental data", 26 January 2017 (2017-01-26), XP055575826, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article/file?type=supplementary&id=info:doi/10.1371/journal.pone.0170903.s010> [retrieved on 20190329] *

Similar Documents

Publication Publication Date Title
AU2019297391B2 (en) Oligonucleotides for modulating Tau expression
US11732262B2 (en) Use of FUBP1 inhibitors for treating hepatitis B virus infection
AU2019291050A1 (en) Oligonucleotides for modulating SCN9A expression
EP3980539A1 (fr) Oligonucléotides antisens ciblant l&#39;atxn3
US20210095277A1 (en) Antisense oligonucleotides targeting srebp1
EP3802824A1 (fr) Oligonucléotides destinés à moduler l&#39;expression de atxn2
WO2020201339A1 (fr) Oligonucléotides pour moduler l&#39;expression d&#39;atxn2
WO2019145386A1 (fr) Oligonucléotides pour la modulation de l&#39;expression de csnk1d
EP3740574A1 (fr) Oligonucléotides pour moduler l&#39;expression d&#39;erc1
EP3724333A2 (fr) Oligonucléotide pour la modulation d&#39;expression du fndc3b
WO2019137883A1 (fr) Oligonucléotides pour moduler l&#39;expression de pias4
EP3737760A1 (fr) Oligonucléotides pour la modulation de l&#39;expression de gsk3b
WO2019115417A2 (fr) Oligonucléotides pour la modulation de l&#39;expression de rb1
WO2023078883A1 (fr) Oligonucléotides pour moduler l&#39;expression de l&#39;apolipoprotéine e4
WO2019038228A1 (fr) Oligonucléotides pour la modulation de l&#39;expression de tom1
WO2019030313A2 (fr) Oligonucléotides pour la modulation de l&#39;expression de ube3c

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19702046

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19702046

Country of ref document: EP

Kind code of ref document: A1